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Abstract 
The atrogin F-box protein plays a role in muscle wasting in many diseases 
including cancer, sepsis, AIDS, renal failure, COPD and more. In mammals, atrogin is a 
component of an E3 ligase that serves to add ubiquitin moieties to, or ubiquitinate, 
substrates. Some targets of atrogin, such as proteins essential for muscle synthesis, are 
ubiquitnated and tagged for degradation. However, other targets, such as foxo, that are 
ubiquitinated have enhanced activity. Although widely studied in vertebrate species, 
atrogin has yet to be characterized in Drosophila melanogaster. In this study, the D. 
melanogaster homologue of atrogin has been identified and characterized. The atrogin 
homologue in Drosophila has been partially conserved through evolution, and retains all 
of the functional domains. When overexpressed, atrogin can show a slight decrease in 
locomotor ability, longevity, ommatidia number and bristle number. When examining 
potential interactions between atrogin and foxo, it was shown that the overexpression of 
atrogin during nutritional stress enhances survivorship. Additionally, the co-expression 
of atrogin andfoxo enhances thefoxo phenotype as seen by a decrease in ommatidia 
number and increase of survivorship during nutritional stress. Finally, it was shown that 
atrogin suppresses the deleterious effect that PI31, a binding partner of FBX07, has on 
the ommatidia) array of the compound eye. 
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Introduction 
The atrogin F-box protein has been found to be overexpressed in a wide array of 
human diseases and conditions such as cancer, AIDS, and sepsis among others where 
muscle wasting can occur. It aids in muscle wasting through its ubiquitin ligase function 
as part of an SCF complex (Russell, 2010). Ubiquitin ligases attach ubiquitin molecules 
onto their specific substrates and are essential to the proper functioning of the cell and 
many of its molecular mechanisms taking place within (Chau et al., 1989). The ubiquitin 
molecules are attached to lysine resides of the substrate. Ubiquitin is a 76 amino acid 
peptide, with seven lysine residues; therefore, they can become targets of ubiquitination 
to form polyubiquitin chains. Hence, there are seven possible chains, and each is 
produced and are different from one another both structurally and func tionally 
(Emmerich et al., 2011). The main focus of this study is the Iysine-48 and Iysine-63 
linked polyubiquitin chains as these have been found to be formed by the atrogin SCF 
complex. The lysine-48 linked chain targets substrates for degradation via the 26S 
proteasome (Chau et al. , 1989) while the Iysine-63 linked polyubiquitin chains have roles 
in protein modification, protein trafficking and DNA repair but is not recognized by a 
proteasome (Chen and Sun, 2009). The wide array of cellular processes that 
ubiquitination can effect highlights the importance of these ligases. 
F-box proteins control the mechanism of ubiquitination as they bind the target 
substrate as a component of an SCF ubiquitin ligase complex. They can have an 
extensive variety of functions within the cell such as plant organ formation and hormone 
response, genomic instability, Drosophila ti ssue development and circadian rhythm. In 
mammals, known targets ofF-box proteins include substrates that can control cell cycle 
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and cell progression. In Caenorhabditis elegans an F-box protein can control 
spermatogenesis. Additionally, the dimerization ofF-box proteins expands their 
functionality as homo and heterodimers may have different functions. Different isoforms 
may localize to different parts of the cell (Ho et al., 2008; Ho et al., 2006). Thus, by 
targeting proteins for degradation or modification, F-box proteins are a component in 
many cellular processes and pathways. 
SCF Ubiguitin Ligases 
Ubiquitin ligases are a part of the ubiquitin proteasome system (UPS), which is 
comprised of three main components (Appendix 1). TheEl ubiquitin-activating enzyme 
serves to activate the ubiquitin molecules via ATP. The E2 ubiquitin-conjugating enzyme 
forms a thioester linkage between the ubiquitin and the E2 (Scheffner et al. , 1995). The 
E3 ubiquitin ligase recognizes the specific protein substrate and attaches the ubiquitin 
molecules to its target (Hershko et al., 1983). There are two types of E3 ligases, one with 
a HECT-domain and the other with a RING-domain. The HECT-domain transfers the 
ubiquitin molecule first from the E2 enzyme, then to the E3 and finally onto the substrate. 
The RING-domain proteins transfer the ubiquitin molecules directly from the E2 onto the 
substrate (Pickart, 2001 a). The orientation in which the chains of ubiquitin molecules are 
attached to each other determine whether or not the substrate may be degraded. The 
lysine-48 linked polyubiquitin chains are recognized by the 26S proteasome for 
degradation, whereas other linkages such as lysine-63 are involved in the modification of 
enzymatic activity (Li et al., 2007a) and the cellular signaling pathways for cell cycle, 
DNA repair, and apoptosis (Passmore and Barford, 2004). These chains may be 
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recognized by ubiquitin binding domains of signalling proteins, and together the target 
protein and signalling protein can carry out their biological function (Chen and Sun, 
2009). Although the Iysine-48 linked molecules are more widely known, the Iysine-63 
linked chains are critical for the proper functioning of the cell. 
One of the most common groups of E3 ligases is the SCF (Skp-Cul-F box) 
complex composed of four proteins; SKP 1, a Cull, ROC 1 and an F-box protein (Cardozo 
and Pagano, 2004 ). ROC 1 is a RING-finger protein that allows for the direct transfer of 
the ubiquitin molecule from the E2 to the target protein (Pickart, 2001 b) interacting with 
Cull to do so. In turn, Cull interacts with SKPI which is bound to the F-box protein (Ho 
et al. , 2006). The F-box protein gives the SCF complex substrate specificity as it binds 
the target substrate through various domains while the F-box motif binds SKP-1 (Bai et 
al., 1996). Thus, the F-box protein controls which protein is to be ubiquitinated and the 
rate of ubiquitination as it binds the substrate. 
F -box Proteins 
F-box proteins are characterized by the presence of an approx imately 50 amino 
acid F-box motif near the carboxyl terminus of the protein (Bai et al., 1996). There are 
three major classes ofF-box proteins classified based upon their substrate interaction 
domain, normally located at the carboxyl terminus. The two prominent domains are the 
WD40 repeat domain (Smith et al. , 1999) and the leucine rich repeat (LRR) domain 
(Kobe and Kajava, 2001) forming the FBXW and FBXL classes, respectively. FBXO, the 
third class ofF-box proteins has various other domains such as CASH, PDZ, zinc-finger, 
and proline-rich domains (Cardozo and Pagano, 2004). The diversity among the F-box 
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proteins reflects the great variety of the target proteins recognized by SCF E3 ubiquitin 
ligases. 
F-box proteins can be found throughout the eukaryotic domain. For example, 33 
F-box proteins have been identified in Drosophila, 600 in Arabidopsis thaliana, 326 in 
Caenorhabditis elegans, 11 in Saccharomyces cerevisiae, 74 in mice and 68 in humans 
(Ho et al. , 2006; Jin et al. , 2004; Kipreos and Pagano, 2000; Ou et al., 2003). Currently, 
F-box proteins have not been found in prokaryotes. The F-box motif may have integrated 
into several different proteins at different times during the evolution of eukaryotes. This 
has been suggested due to the variety of secondary motifs found in F-box proteins. Each 
of the three classes has different evolutionary constraints, where FBXW and FBXL are 
more highly conserved than FBXO. Within the F-box motif, there are very few amino 
acids that are invariable between species (Kipreos and Pagano, 2000), indicating that the 
structure ofF-box proteins may not be as highly conserved as other proteins. 
Ubiquitination is not the only function ofF-box proteins within the SCF complex. 
They can regulate the neddylation of their specific substrates such as cull ins (Cope and 
Deshaies, 2003) and p53 in humans (Abida et al. , 2007). In Saccharomyces cerevisiae, 
two F-box proteins control mitochondrial fusion and tubule formation (Durr et al. , 2006), 
and in many flowering plants the s-locus F-box can inhibit self-fertilization (Qiao et al., 
2004). The ability ofF-box proteins to function in many different cellular aspects 
highlights their importance in the proper functioning of cells. 
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FBX032 (atrogin) the E31igase F-box protein 
Vertebrate atrogin is an F-box protein that functions as a part of an SCF complex. 
The protein contains a PDZ domain instead of the WD40 and LRR domains common to 
many F-box proteins and is classified as FBX032. In addition, the protein contains a 
leucine charged domain, leucine zipper domain, nuclear localization sequence (NLS) as 
well as a nuclear export sequence (NES) (Bodine et al. , 200 la; Julie et al., 20 12; Li et al., 
2007b; Tacchi et al., 2010). The presence of both the NLS and NES indicates that both 
nuclear and cytosolic proteins are likely to be substrates of atrogin. 
The expression of atrogin has been found to be upregulated in skeletal muscles of 
several species undergoing muscle wasting including mice, rats, salmon, humans and 
Drosophila. Skeletal muscle atrophy occurs as a result of a decrease in protein synthesis 
along with an increase in the degradation of proteins necessary for synthesis. The 
majority of the increase in proteolysis is due to an increase in the activation of the UPS 
(J agoe and Goldberg, 200 I ), of which atrogin is a component. After two weeks of 
induced immobilization in humans, atrogin increased approximately 34%, and then 
decreased upon rehabilitation (Jones et al., 2004). Increased expression of atrogin has 
been found in amyotrophic lateral sclerosis (ALS) (Leger et al., 2006), paraplegia, 
chronic obstructive pulmonary disease (COPD) and limb immobilization (Russell , 20 10). 
In mice, the expression of atrogin has a demonstrated increase of nearl y I 0 fo ld in 
skeletal muscle, after two days of fasting, where only one other E3 enzyme, MuRFI, was 
significantly upregulated (Jagoe et al., 2002). In starved mice, atrogin expression was 
increased in contrast to fed animals (Bodine et at. , 200l a). In rats, atrogin mRNA was 
increased in models of fasting, diabetes, renal failure and cancer (Lecker et al. , 2004). In 
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both Atlantic salmon and rainbow trout, atrogin was increased under starvation 
conditions (Cleveland and Evenhuis, 2010; Tacchi et al., 2010). Finally in Drosophila, 
the proposed atrogin homologue, CGJ 1658, is upregulated in the muscle wasting mutant 
(mute) by 30% (Bulchand et al., 2010). Conversely, when the expression of atrogin is 
knocked out, there is a decrease in muscle loss in animal models. In mice lacking 
functioning atrogin, muscle wasting is decreased by 50% after denervation (Latres et al., 
2005). Taken together, these findings indicate that atrogin is important for muscle 
degradation. 
MyoD has been identified as a substrate of atrogin and may be primarily 
responsible for the decrease in muscle synthesis when atrogin expression is increased. 
MyoD is a member of a family of helix-loop-hel ix transcription factors (Edmondson and 
Olson, 1993) that include myogenin (Wright et al. , 1989), myfS (Braun et al., 1 989) and 
MRF4 (Rhodes and Konieczny, 1989). They are able to activate muscle-specific genes 
and cause an arrest in the cell cycle (Zhang et al., 1999). This cell cycle arrest promotes 
the differentiation of myoblasts into myotubes during the process known as myogenesis. 
The E3 ligase contai ning atrogin binds to MyoD via the leucine charged domain on the F-
box protein, and places ubiquitin molecules on a lysine amino acid in MyoD within the 
nucleus. These ubiquitin molecules are linked through lysine-48, therefore MyoD is 
targeted for degradation by the ubiquitin proteasome system (Tintignac et al., 2005). 
Once MyoD is targeted for degradation there is a decrease in muscle synthesis and 
muscle wasting can begin to occur. 
Another essential protein for muscle synthesis which atrogin targets for 
degradation is the eukaryotic initiation factor-3 subunit 5 (eiF3-f), which plays a role in 
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the terminal differentiation of skeletal muscle (Fraser et al., 2004). The protein is a key 
player in the crossover between the atrophy and hypertrophy pathways in skeletal muscle, 
which is partially regulated by the insulin receptor signalling pathway (Holz et al., 2005). 
When thi s pathway is activated, hypertrophy is induced, in part by the activation of eiF3-
f. However, in the absence of insulin or insulin-like growth factor-1, thi s pathway is 
inactivated and the expression of atrogin is enhanced (Csibi et al. , 2008). The E3 ligase 
of which atrogin is a component can then target eiF3-f for lysine-48 linked 
polyubiquitnation, and eiF3-f is degraded by the 26S proteasome (Lagirand-Cantaloube 
et al., 2008), to induce atrophy. 
Another role of atrogin is the inhibition of cardiac hypertrophy caused by 
calcineurin. Calcineurin is a serine/threonine phosphatase that acts to dephosphorylate the 
transcription factor NF-AT3. The end result of this intracellular pathway is an increase in 
cardiac hypertrophy (Molkentin et al. , 1998). In the cardiac muscle cells, calcineurin is 
attached to a-actinin-2 to begin its activation (Frey et al., 2000). The calcineurin/a-
actinin-2 complex is recognized by atrogin, and calcineurin is tagged with a lysine-48 
linked polyubiquitin chain through the UPS and is degraded by the 26S proteasome (Li et 
al., 2004). Without calcineurin present, the pathway leading to cardiac hypertrophy is 
halted. 
The foxo transcription factors and the insulin receptor signalling pathway 
The foxo (forkhead box subgroup "o") transcription factors (Biggs et al., 2001) 
were first discovered as a proto-oncogene that led to alveolar rhabdomyosarcoma (Sublett 
et al., 1995). The foxo proteins are characterized by the presence of the DNA binding 
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forkhead domain (Lai et at., 1993). There have been several versions of foxo identified 
in humans and mice as foxo I, foxo3 , foxo4, foxo6 (Jacobs et al., 2003) and foxo I, foxo2 
and foxo4, respectively (Biggs et al., 2001 ). Homologues have been identified in C. 
elegans as daf-16 (Gottlieb and Ruvkun, 1994) and in D. melanogaster (Junger et al., 
2003; Kramer et al. , 2003; Stitt et al., 2004). The evolutionary conservation of the foxo 
family of transcription factors points to the importance they hold in all organisms. 
One of the most crucial pathways foxo functions in is the insulin receptor 
signalling pathway, including the serine/threonine kinase akt, a key regulator of the foxo 
transcription factor family (Brunet et al., 1999). Insulin and insulin-like growth factor I 
(IGF-1) can serve as survival factors to activate the insulin receptor signalling pathway to 
prevent apoptosis of the cell. IGF-1 binds their receptor tyrosine kinase to begin the 
intracellular signalling. The receptor tyrosine kinase activates phosphatidylinositol 3-
kinase (P1 3K) through insulin receptor substrate (IRS) 1-4 (Coffer et al., 1998). PI3K 
generates the second messenger phosphatidylinositol (3,4,5)-triphosphate (PIP3) by 
phosphorylating phosphatidylinositol-4,5-bisphosphate (PIP2). The akt kinase is recruited 
to the membrane through its pleckstrin homology (PH) by PIP3, where akt then becomes 
phosphorylated by PDKI (Franke, 2008). The akt kinase can then phosphorylate foxo at 
three di stinct sites; threonine 32, serine 253 and serine 315 (Brunet et al. , 1999). Once 
phosphorylated, binding sites for proteins 14-3-3 are created on foxo and the joining of 
the two proteins inactivates foxo and sequesters it in the cytoplasm (Cahill et at., 2001 ). 
Since foxo is excluded from the nucleus, it is unable to activate the transcription of its 
target genes. Conversely, the insulin receptor signalling pathway can be inhibited, which 
favours the activation of foxo. In this case, akt remains inactive and foxo remains active, 
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which leads to its retention in the nucleus where it can initiate the transcription of its 
target genes (Ramaswamy et al. , 2002). Therefore, the amount of insulin or IGF-1 
determines the balance between foxo activation and deactivation. 
This intracellular signalling pathway is evolutionarily conserved between D. 
melanogaster and humans. In Drosophila, the insulin receptor signalling pathway can 
control body size, metabolic response, longevity and stress resistance (Oldham et al., 
2000; Puig and Mattila, 2011) through seven Drosophila insulin-like peptides (Dilps). 
The Dilps are able to act as ligands for the Drosophila insulin receptor (Inr) (Brogiolo et 
al., 200 I) and can follow through the insulin signalling pathway in a remarkably similar 
manner to that previously described in mammals. Once the Dilps are bound to the Inr, the 
Inr undergoes autophosphorylation (Ruan et at. , 1995) and recruits the Drosophila IRS 
homologue, chico (Bohni et al., 1999). Drosophila PI3K is directed to the membrane by 
phosphorylated chico and is then activated. This leads to the generation of PIP3, which 
directs Drosophila akt to the membrane to become activated (Cantley, 2002). The akt 
kinase then acts to inactivate the single Drosophila foxo homologue, foxo (Junger et al., 
2003; Kramer et al. , 2003). The evolutionary constraints on foxo due to its significance 
has conserved its function between humans and Drosophila. 
The family of foxo transcription factors has been implicated in a number of 
cellular pathways including cell cycle arrest, differentiation, survival and apoptosis 
(Barthel et al., 2005). The mammalian homologues of foxo can play a role in reactive 
oxidative stress response and tumour formation (Tzivion et al., 2011 ). In Drosophila 
melanogaster, the foxo homologue negatively regulates the process leading to growth 
(Kramer et al. , 2003) and in Caenorhabditis elegans, daf-16 is essential for entry into the 
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dormant dauer state (Gottlieb and Ruvkun, 1994). The foxo proteins accomplish all this 
through the initiation of transcription of its target genes. For example, p27Kipl is a target 
gene in humans that can control cell cycle (Medema et al. , 2000). In Drosophila, foxo 
initiates the transcription of 4E-BP that inhibits growth (Junger et al., 2003). 
Additionally in C. elegans, daf-16 has been found to regulate daf-15, which participates 
in regulating longevity (Jia et al., 2004). Throughout all species, foxo homologues play a 
very important role in the growth and development of the organism. 
The insulin signalling pathway and foxo can play an important role in muscle 
wasting. Glucocorticoids act to inhibit the insulin receptor signalling pathway, to result in 
akt not becoming phosphorylated (Konagaya et al., 1986). Without the presence of 
phosphorylated akt, foxo has a tendency to not become phosphorylated and, therefore, 
deactivated. This leaves foxo free to enter the nucleus and initiate the transcription of the 
"atrogenes" (genes that stimulate muscle atrophy). The atrogenes include cathepsin L 
(Komamura et al., 2003), PDK4, p21, MURFJ and atrogin (Lecker et al., 2004; 
Schakman et al., 2008). Together, these genes can act to increase muscle wasting. 
Muscle wasting occurs when essential proteins are degraded by the 26S 
proteasome when tagged with lysine-48 linked ubiquitin molecules. The foxo 
transcription factors play a key role in the production of these ubiquitin molecules. When 
the MEK kinase/extra cellular signal-regulated kinase (ERK) pathway is activated by the 
presence of glucocorticoids, the end result is an increase in single ubiquitin molecules. 
This is accomplished through Sp 1, which is able to bind the ubiquitin promoter and is 
regulated by MEK/ERK (Marinovic et al., 2002). Activated foxo increases IRS-2 
presence in the cell membrane, which in tum increases the activity of the MEK/ERK 
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pathway (Zheng et al., 20 I 0). Therefore, an increase in the activation of foxo indirectly 
causes an increase in the amount of free ubiquitin present in the cell. The free ubiquitin 
molecules are then made available to be used by atrogin and the UPS to target muscle 
synthesis proteins to be degraded. As a result, the activation of foxo leads to increased 
proteolysis in two manners; by initiating the transcription of atrogenes and by increasing 
the availability of monomeric ubiquitin molecules. 
A positive feedback mechanism: atrogin and foxo 
As discussed, vertebrate atrogin is an F-box protein and acts as a component of an 
SCF complex that functions as an E3 ligase (Bodine et al., 200 I a). The F-box protein 
binds substrates, and therefore determines the targets of ubiquitination in the UPS. One of 
the major targets of atrogin is the foxo family of transcription factors. This was first 
discovered in models of cardiac hypertrophy in mice where atrogin was found to suppress 
the hypertrophy caused by insulin and IGF-1. When foxol and foxo3 were examined, it 
was found that atrogin decreased akt-dependent phosphorylation of both proteins by 55-
60%. However, the levels of foxo in the cardiomyocytes do not decrease in the presence 
of atrogin, indicating that atrogin is not targeting foxo for proteasomal degradation. 
Instead, atrogin tags foxo with a polyubiquitin chain that is linked by the ubiquitin's 
lysine 63. The noncanonical ubiquitination of foxo sequesters the transcription factors in 
the nucleus (Li et al., 2007a). Thus under these circumstances, akt does not 
phosphorylate and thereby inactivate the role of foxo as a transcription factor. 
Studies have shown in mammals that when the insulin receptor signalling 
pathway has decreased activity, there is an increase in muscle atrophy (Bodine et al. , 
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2001 b) and atrogin expression (Sacheck et al., 2004). Conversely, when the insulin 
signalling pathway is activated, muscle atrophy is suppressed (Rommel et al., 2001). The 
phosphorylated state of foxo is critical to the atrophy program. It is essential that foxo be 
inactivated for muscle atrophy to be blocked by the insulin receptor signalling pathway. 
The atrogin gene is a target of foxo and can tri gger skeletal muscle atrophy when insulin 
or IGF-1 are absent. Without either of these activators, the insulin signalling pathway 
remains deactivated and akt unphosphorylated. Therefore, foxo is not phosphorylated and 
is able to localize in the nucleus. Once inside, foxo binds the promoter region of atrogin 
near theTA TA box and the transcription start site (Sandri et al., 2004; Stitt et al., 2004 ). 
Taken together, these studies show that atrogin and foxo work together in a positive 
feedback mechanism where an increase in one protein leads to an increase in the other 
(Figure 1). 
Myostatin-induced muscle atrophy is another way by which foxo initiates the 
transcription of atrogin. Myostatin is negative regulator of growth and does so by down-
regulating the insulin receptor signalling pathway, thereby activating foxo I , which can 
then initiate the transcription of atrogenes including atrogin (McFarlane et al. , 2006). 
Also, myogenin activates the ActRIID pathway that phosphorylates Smad2, which 
induces the transcription of foxo transcription factors (Lokireddy et al. , 20 ll a). Thus, 





Figure 1: The foxo family of transcription factors and atrogin work together in a 
positive feedback loop. Insulin and/or IGF- l binds to the receptor tyrosine kinase which 
activates PI3K through the insulin receptor substrate (not shown). PI3K then 
phosphorylates PIP2 to form PIP3 that recruits akt to the cell membrane where akt 
becomes phosphorylated . Phosphorylated akt then acts to phosphorylate foxo, excluding 
it from the nucleus. In the absence of insulin signalling, foxo is dephosphorylated and 
enters the nucleus to initiate the transcription of its target genes, including atrogin. The 
atrogin protein can then form an SCF complex and tag foxo with a lysine-63 linked 
polyubiquitin chain, which may block the interaction between akt and foxo (indicated by 
the x), thereby retaining foxo in the nucleus. Figure edited from (Schi sler et al., 2008). 
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Drosophila melanogaster as a model organism 
Drosophila melanogaster is used as a model organism to study human diseases 
and cellular pathways. The Drosophila genes are remarkably similar to human 
genes, where approximately 75% of all human disease genes have Drosophila 
homologues. It is advantageous to use D. melanogaster due to their easy and inexpensive 
maintenance, short generation times (from egg to adult in ten days), large number of 
progeny, plus a lessened concern of the ethical issues of an invertebrate animal system. 
The Drosophila genome and intracellular pathways tend to be much simpler than their 
mammalian counterparts. The genetic redundancy found in mammals can inhibit the 
research of knock-out or mutated genes. Drosophila does not have the same amount of 
redundancy (Bier, 2005), and therefore the loss of function of genes can be more easil y 
examined. Several models of human muscular diseases currently exist in Drosophila. 
These include spinal muscle atrophy, Duchene and Becker muscular dystrophies, and 
myotonic dystrophy among others (Lloyd and Taylor, 2010). In patients diagnosed with 
several of these conditions, atrogin has been demonstrated to have increased levels of 
expression (Russell , 201 0). Therefore, by initiating a study of the Drosophila atrogin 
homologue, such muscle wasting diseases can be modeled and the biological basis of 
these diseases can be better understood. 
Genetic techniques in Drosophila melanogaster 
An essential technique commonly used in Drosophila research is the UAS-GAL4 
system of ectopic gene expression (Appendix 2). This approach allows the directed 
expression of target genes in a tissue specific pattern including the eyes, neurons, muscles 
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or the whole body. The system was designed to have two separate entities; the yeast 
transcription factor GAL4, under the control of a tissue or temporally specific promoter, 
and the upstream activating sequence (UAS) situated to control a gene of interest (Brand 
and Perrimon, 1993). Each component is generated and maintained in separate transgenic 
fly lines, and only when the two lines are crossed is the target gene expressed in the 
critical class progeny. The UAS contains binding sites for the GAL4 proteins and is fused 
to the target gene. Therefore, when the two lines are combined, GAL4 binds the UAS and 
turns on the transcription of the gene of interest. However, when these lines remain 
separated the gene is silent. In the GAL4 line, the UAS binding sites are not present and 
transcription is not activated. In the UAS line the activating transcription factors are 
absent, and the gene again remains silent (Phelps and Brand, 1998). The separation of the 
two components allows for a broad range of combinations of expressing target genes in 
specific cell and tissue patterns. 
Another critical genetic approach that has been developed in Drosophila 
melanogaster is the transposable P-element. As seen in this study, the P-element can be 
excised from the genome in a manner that may cause a deletion of neighbouring genes to 
generate independent loss-of-function mutations. More recently, a system that couples 
interference RNA (RNAi) with the UAS/GAL4 system has been developed in Drosophila 
(Dietzl et al., 2007) to allow the study of transcriptional "knock down" effects. Thus, 
there are multiple ways to study the loss of function of genes in Drosophila. 
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Goals of this Research 
The purpose of this study is to begin the characterization of the potential atrogin 
homologue in Drosophila melanogaster, gene CG 11658 (Gomes et al., 200 I). Through 
bioinformatic analysis, the conservation between atrogin and its mammalian 
homologues, as well as its relationship to other F-box proteins, will be determined. 
Studies of the consequences of overexpression, both in the developing eye and in a 
ubiquitous manner, will expand our understanding of atrogin activities. Examination of 
the potential interaction of atrogin with foxo in Drosophila will provide greater 
knowledge of the conservation of the control of the balance between cell death and 
survival where foxo acts as main regulator. 
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Materials and Methods 
Bioinformatic Analysis 
Identification of Drosophila homologue of atrogin from human sequence 
The Drosophila melanogaster homologue of atrogin was identified using the 
National Centre for Biotechnology Information's (NCBI) tBLASTn search tool. The D. 
melanogaster genomic sequences were searched using the amino acid sequence of the 
human atrogin protein (accession number NP _ 478 136. 1 ). The Drosophila homologue 
was identified as gene CG 11658. 
Identification of additional homologues, multiple alignment and domain 
identification 
Homologues of Drosophila melanogaster atrogin were identified using the 
NCBI's Homologene and Basic Local Alignment Search Tool (BLAST). The D. 
melanogaster atrogin sequence was queried against the BLAST database. Sequences 
were aligned using ClustaiW (Larkin et al, 2007) to show sequence similarity. The F-box 
domain was identified through manual analysis using the F-box motif consensus 
sequence (Willems et al. , 1999). The nuclear localization sequences (NLS) were 
identified using PSORT II Prediction and through literature research (Julie et al. , 201 2). 
H. sapiens and M. musculus PDZ domains were taken from literature (Gomes et al. , 
200 I ), and the D. melanogaster and A. gambiae PDZ domains were identified through 
manual analysis. The cladogram was constructed by the maximum parsimony method 




All fly stocks were maintained on a standard medium of 10 g/L yeast, 5.5 g/L 
agar, 65 g/L cornmeal and 50 milL molasses and stored at room temperature. The 
medium was treated with propionic acid (0.25%) and methylparaben in ethanol (0.05%) 
to prevent mold growth. Approximately 7 mL of medium was allowed to solidify per 
vial. The medium was prepared by Dr. Brian E. Staveley approximately twice a month 
and stored at 4 to 6°C until use. 
Drosophila stocks 
All Drosophila stocks were obtained from the Bloomington Drosophila Stock 
Centre unless otherwise noted. The atrogin mutant lines used were 
y' w67c23 ; P(EPgy2}CGJJ658EYJOJJS (atgnEY) stock number 17663 and y1 ; P(SVPor-
p }CG 1 1658Kcos620 ry506 (atgnKG) stock number 14743. The atgnEY mutants (homozygotes) 
have an EPgy2 P-element insertion which contains a GAL4 responsive upstream 
activating sequence and a transcriptional unit to drive the expression of the atrogin gene 
in the presence of GAL4. Absence of GAL4 may cause a loss of function of the gene. 
The atgnKG mutants (homozygotes) contain the SUP P-element that serves to inactivate 
the atrogin gene, thereby creating a loss of function mutant. The control w11 18 line was a 
generous donation from Dr. Howard Lipshitz (University of Toronto). Recombinant lines 
GMR-GAL4; UAS-foxo1, GMR-GAL; UAS-m-foxo, GMR-GAL4; UAS-foxoH1, GMR-
GAL4; UAS-foxoH1 ; atgnEY, GMR-GAL4; atgnEY, and UAS-P/31; atgnEY were prepared 
by Dr. Brian E. Staveley (unpublished). The GMR-GAL4; UASjoxoH1 was created by 
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Table 1: Genotypes of all stocks used to characterize atrogin in this study. 
Genotype Abbreviation Expression Balancer Reference 
Pattern 
Control Lines 
w; VAS-lacZ:-l -? VAS-lacZ (Brand et al. , 
1994) 
w w (Bingham et 
al. , 1981) 
Driver Lines 
w; GMR-GAIA - GMR-GAIA Eye (Freeman, 
1996) 
y w; act-GAIA/CyO, y + act-GAL4 Ubiquitous CyO (Brand and 
Perrimon, 
1993) 
w*; P{GAIA-armj.S1 1 arm-GAlA Ubiquitous (Sanson et 
al. , 1996) 
I ~ y w ; P{GAIA-Mej2}.R3 mef-GAIA Muscle Schnorrer, F., 
20091 
UAS Lines 
w; VAS-b-akt · VAS-b-akt (Staveley et 
al. , 1998) 
w; VAS-akt · VAS-akt (Staveley et 
al., 1998) 




atgn (Bell en et al. , 
P{ EPgy2}CGI 1658EYIOJIS 2004) 
y ; P{SVPor- atgn (Bell en et al., 
p }CG 11 658Kc08620 ry506 2004) 
Recombinant Lines 
w; GMR-GAIA!CyO; GMR-GAIA; Eye (Kramer et 
VAS-foxo 1!TM3 VAS-foxo 1 al., 2003) 
w; GMR-GAIA VAS-m- GMR-GAIA; Eye CyO (Kramer et 
foxo!CyO VAS-m-foxo al. ,2003) 
w; GMR-GAIA VAS- GMR-GAIA; Eye CyO Staveley, 
joxoH1/Cy0 VAS-foxo HI uneublished 
w; GMR-GAIA VAS- GMR-GAIA; Eye CyO Staveley, 
joxoH1/Cy0; atgnEY!TM3 VAS-foxoH 1 ; TM3 unpublished 
atgnEY 
GMR-GAIA/CyO ; GMR-GAIA; Eye CyO Staveley, 
atgnEYfTM3 atgnEY TM3 uneublished 
VAS P/31 ; atgn£Y!TM6B VAS-P/31; TM6B Staveley, 
EY 
uneublished atgn 
1- Personal communication to Flybase; http://flybase.org/reports/FBrf0207880.html 
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mobilizing the original GMR-GAIA; UAS-foxo 1 insertion on the third chromosome by P-
element transposition. The novel insertion into the second chromosome was isolated by 
standard genetic means. Recombinant lines GMR-GAIA; UAS-foxo 1 and GMR-GAIA; 
UAS-m-foxo were previously described (Kramer et al., 2003). See Table 1 for full list of 
all genotypes used. 
Drosophila crosses 
To determine effects of overexpressing atrogin, crosses were established of three 
to four virgin females mated with two to three males. Control crosses were set up using 
UAS-lacZ and/or w1118 and were kept on standard medium at 25°C. The crosses were 
transferred onto fresh food every three to four days to increase the number of progeny. 
Critical class males were selected for each assay. Critical class males are defined as those 
not expressing dominant mutant phenotypes associated with balancer chromosomes such 




Approximately 70 critical class males were collected from crosses as described. 
Flies were placed in vials of fresh Drosophila medium with ten flies per vial and kept at 
25°C. Two days after collection, flies were scored for their climbing ability. They were 
then scored every seven days until discontinued. Climbing ability was assayed using a 
climbing apparatus consisting of a 30 em glass tube with a 1.5 em diameter that was 
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marked with five 2 em sections along with a buffer zone (Todd and Staveley, 2004) 
(Appendix 3). Each vial was climbed ten times and the flies were scored based on which 
section they had reached after ten seconds. Climbing ability was determined using the 
climbing index L(nm)/N where n is the number of flies in the given section, m is the 
section (1-5) and N is the total number of flies climbed in the given trial. Data was 
analyzed using GraphPad Prism 5 (GraphPad Software, Inc.). The climbing index was 
subtracted from five and a non-linear regression curve was fit to each data set. Slopes of 
the curves were compared using a 95% confidence interval. Significance was considered 
by the overlapping of the 95% confidence interval. 
Longevity Assay 
Critical class males were selected for each longevity assay from crosses as 
described. From here, the critical class males were selected upon eclosion. The males 
were collected daily and placed in vials containing fresh standard medium. 
Approximately three hundred flies were collected with no more than 20 flies in a single 
vial to prevent over crowding. Flies were scored every two days for the presence of dead 
flies. Flies were considered dead when no movement occurred when agitated (Staveley 
et al., 1990). Data was analyzed using GraphPad Prism 5.0 (GraphPad Software, Inc.) 
using the log-rank test with significance considered at p < 0.05 . 
Starvation Longevity Assay 
Critical class males were collected from crosses described above. For assays of 
stock genotypes, the stock collection of flies were flipped onto fresh food and placed at 
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25°C. Approximately three hundred males were collected and placed on starvation 
medium with no more than 20 flies per vial to prevent over crowding. Starvation medium 
consists of agar and 5% sucrose in a phosphate-buffer-saline (PBS) solution. Flies were 
aged and kept at 25°C. Flies were scored every two days for the presence of dead flies. 
Flies were considered dead when no movement occurred when agitated (Staveley et al., 
1990). Data was analyzed in GraphPad Prism 5 (GraphPad Software, Inc.) using the log-
rank test with significance considered at p < 0.05. 
Biometric Analysis of the Compound Eye 
Critical class males were collected by setting up crosses as previously described, 
and were aged for three to five days on standard Drosophila medium at 25°C. They were 
frozen and stored at -80°C until use. Flies were mounted on aluminum studs with the left 
eye facing upwards and desiccated for at least 12 hours. All studs were gold coated using 
the Electron Microscopy Science 500 Sputter Coater and micrographs were taken at 
150X magnification with the Hitachi S-570 Scanning Electron Microscope (SEM) or 
with the FEI Quanta 400 Environmental SEM. These micrographs had a magnification of 
543X and a horizontal field width of 550 flm. Micrographs were analyzed using IrnageJ 
(Abromoff et al., 2004) where total number of ommatidia, ommatidium area and numbers 
of bristles were determined. Ommatidium area was analyzed by measuring the total area 
of three groups of seven ommatidia and the average was taken. Data was analyzed using 
Graphpad Prism 5 (Graphpad Software Inc.) where mean± standard error of the mean 
was calculated. Unpaired t-tests were used to determine significance where significance 
was considered at p < 0.05. 
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Analysis of novel atgnEY mutants 
Dr. Brian E. Staveley created all atgnEY mutants by excising the EPgy2 P-element 
from atgnEY andre-isolating w deri vatives for the loss of the transposons's w + transgene. 
DNA extraction of atgnEY mutants 
Ten critical class males of each genotype were collected in a 1.5 mL Eppendorf 
tubes and stored at -80°C. The mutants atgn6, atgn8, atgn13a, atgn14a, atgn14b, atgn18, and 
atgn19 were not viable as homozygous adults, therefore approximately I 0-15 critical class 
larvae were collected and stored in the same manner. DNA extraction was carried out in 
500 Jll of squishing buffer (10 mM Tris-HCL, 1 mM EDTA and 25 mM NaCl) which 
contained 8.7 Jll of 23 mg/ml proteinase K (Gloor et al. , 1993). The samples were then 
incubated at 37°C for 30 minutes. The samples were cleaned using 250 Jll of phenol and 
chloroform then centrifuged for 10 minutes at 10 000 RPM at 4°C and the top aqueous 
layer was collected. One milliliter (1 mL) of95% cold ethanol along with 10 J.!L sodium 
acetate were used to precipitate the DNA overnight at -20°C. The precipitated DNA was 
then centrifuged at I 0 000 RPM at 4 oc for 15 minutes. The supernatant was decanted and 
the DNA was washed with a series of 70% ethanol washes and allowed to dry before 
resuspension in 500 Jll of ddH20. 
Polymerase Chain Reaction of atgnEY mutants 
The atgnEY excision mutants were characterized by polymerase chain reaction 
(PCR) to determine the range of DNA excised. Primers were designed using Primer3 
(Rozen and Skaletsky, 2000). Primer sets atgn F4 atgn RJ, atgn F4 atgn R6 and atgn F8 
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atgn RJ were located outside the atrogin gene on either side the P-element to determine if 
the P-element still remained. Primer sets atgn F4 atgn R5 and atgn F7 atgn RJ were 
located both within and P-element and the atrogin gene to determine if any of the gene 
was excised with the P-element. See Table 2 for primer information and Figure 2 for 
schematic diagram. PCR reaction mixes were prepared with 36 j..tl of double distilled 
water (ddH20), 5 j..tl of lOX PCR buffer (Qiagen), 2 j..tl dNTP's (Qiagen), 2 j..tl of both 
primers, 1 j..tl (1 ng/j..tl) of template DNA and 0.3 j..tl of HotStarTaq Plus DNA polymerase 
(Qiagen). For PCR with primer sets atgn F4 atgn R6 and atgn F8 atgn RJ, 2 j..tl of MgCh 
(Qiagen) was also added. PCR profile for all primer sets were 95°C for a five minute hot 
start, 94°C for a one minute denaturation, 54°C (atgn F4 atgn RJ, atgn F4 atgn R5, atgn 
F7 atgnRJ) or 55°C (atgn F4 atgn R6, atgn RJ atgn F8) for a five minute annealing, 
72°C for a five minute extension followed by final extension for ten minutes at 72°C and 
a 4°C hold. 
Sequencing of atgnEY excision mutants 
Preparation and sequencing of PCR products obtained from atgnEY excision 
mutants were performed at the Genomics and Proteomics Facility (GaP) at Memorial 
University of Newfoundland via the ABI 3730. Sequences were analyzed by using 
Sequence Scanner Software by Applied Biosystems. 
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Table 2: Characteristics of primers used to classify atgnEY derivative mutants. 
Primer Sequence Length Tm Percent 
(nucleotides) GC 
content 
atgn F4 CTTGCTGGGAA CGGTACTTT 20 59.24 50.00 
atgn F7 AAACCGGTGATAGAGCCTGA 20 59.69 45.00 
atgn F8 GGACTACGCGCTCAACTAGG 20 60.04 60.00 
atgn F9 GTTTATGAGGCCCAACAGGA 20 59.93 50.00 
atgn R3 ATGGGGCACGTTCTGGTA 18 59.92 55 .56 
atgn R5 TTTGGGAGTTTTCACCAAGG 20 59.94 45.00 
atgn R6 GCCCATATAAGGAGCGATGA 20 60.02 50.00 
atgn R7 ATGCTCCACTTCCCGAATTA 20 59.53 45.00 
F7 F8 F9 
I 
atgn (8475 bp) EPgy2 (10 872 bp) mtTFB1 (1640 bp) 
~ 
UAS 
R7 R6 R3 RS 
Figure 2: Schematic representation of atrogin and position of primers used to 
characterize atgnEY mutants. Sizes of pertinent PCR fragments are as foll ows: 
atgnF4/atgnR3 - 500 bp, atgnF4/atgnR6- 1700 bp, atgnF8/atgnR3 - 1700 bp, atgn 
F4/atgnR5 - 650 bp and atgnF7/atgnR3- 500 bp as seen in Table 12. Arrow indicates 
direction of the upstream activating sequence. 
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Generation of UAS-atrogin transformants 
Cloning of atrogin coding DNA sequence into p[PUAST] 
The 2015 base pair coding region of atrogin was obtained as the eDNA clone 
LD30288 in a pOT2 vector from the Drosophila Genomics Research Centre (DGRC), 
Indiana University. A portion of the stab culture was transferred to an LB-
chloramphenical plate and allowed to grow overnight at 37°C. The LD30288-pOT2 DNA 
was obtained through the Plasmid Midi Prep kit (Qiagen) per manufacturers protocol. 
The gene was excised out of the pOT2 vector using EcoRI and Ssp!, separated by gel 
electrophoresis on a 1% agarose gel in lx Tris-acetate-EDTA buffer, and purified using 
QIAquick Gel Extraction kit (Qiagen) following manufacturer's protocol. The fragment 
was ligated into the pT7T3-19U vector, which had been previously cut with EcoRI and 
Smai. The coding region was first cloned into the pT7T3-19U vector as LD30288 has no 
readily exploitable restriction sites, to allow for simple insertion into p[PUAST]. By 
ligating the insert into pT7T3-19U, more restriction sites were available for the cloning of 
the open reading frame (ORF) of LD30288. The LD30288-pT7T319U vector was 
transformed into DHSa Escherichia coli cells prepared by Dr. Brian E. Staveley. Through 
blue-white screening, colonies were selected which held the insert. Through restriction 
analysis using EcoRI, it was determined that the vector contained the insert in the correct 
orientation. LD30288 was excised from pT7T3-19U using EcoRI and Xbal and was again 
isolated as previously described. Once isolated, the insert was ligated into the p[PUAST} 
vector cut with the EcoRI and Xbal. Additionally, 0.3 J.!l of bovine serum albumin (BSA) 
was added to each final digestion to increase yield. Once ligated, it was transformed into 
DHSa E. coli cells, and colonies were analyzed for the presence of LD30288 ORF-
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pUAST though restriction digests with Hindlll. Once identified, this construct was 
designated as P-UAS-atrogin; w +construct 1, and Midi prep was preformed. 
Germline transformation 
To generate germline transformants, the P-UAS-atrogin; w+ vector was injected 
into pre-cellularized, less than 1-hour old w1 118 embryos along with the helper plasmid 
pHS-n (Steller and Pirrotta, 1986). The helper plasmid contains the gene encoding the 
transposase required to insert the DNA into the Drosophila genome but cannot, itself, 
transpose. Once developed, the surviving injected adults were mated with virgin w1 118 
flies and critical class progeny were collected. Critical class progeny, potential P-UAS-





The atrogin sub-family ofF -box proteins are moderately evolutionarily conserved 
Due to the fact atrogin has yet to be examined in Drosophila, bioinformatic 
analysis was conducted. F-box proteins FBX07 (nutcracker), FBX09, FBX025 and 
FBX032 (atrogin) demonstrate that they are all evolutionarily conserved from arthropods 
to mammals (Figure 3). Within the sub-group, FBX07 and FBX09 are most similar, 
with FBX032 more distant and FBX025 less similar. Notably, a homologue of FBX025 
was not found in invertebrates. When the human protein sequence of FBX025 was 
searched against the D. melanogaster, A. gambiae, and A. echinatior genomes using 
BLASTp the FBX032 sequences were the top results, indicating no FBX025 
homologue, other than atrogin. Although D. melanogaster CG5961 does not seem to 
have been previously studied as a homologue of FBX09, it does have sufficient 
similarity to FBX09, therefore it can be tentatively assigned as the Drosophila 
melanogaster homologue. 
The atrogin protein is conserved between vertebrates and invertebrates 
The multiple alignment of vertebrate and invertebrate versions of the atrogin 
protein was prepared using sequences from D. melanogaster (NP _648498.1 ), A. gambiae 
(XP _320404.2), M. musculus (NP _080622.1) and H. sapiens (NP _ 478.136.1). When 
comparing these four species, the atrogin protein has 26% identical residues and 63% 
similar resides among the species. The alignment shows a common highly conserved F-
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Figure 3: A subset of FBXO genes are evolutionary conserved between vertebrates 
and invertebrates. Cladogram created using the max imum parsimony method and 
bootstrapped I 00 times. The Genbank accession number for H. sapiens FBX07 is 
NP _036311 .3, FBX09 BAD93070.1 , FBX032 NP _ 478136.1 , FBX025 NP _904357.1 ; 
forM. musculus FBX07 NP _694875.2, FBX09 NP _076094.2, FBX032 NP _080622.1, 
FBX025 NP _080061 .1; for D. rerio FBX07 NP _00 1020670. 1, FBX09 NP _9560 12.1 , 
FBX032 NP _957211.1 , FBXO 25 NP _991287.1; for A. echinatior FBX07 EGI585 19.1, 
FBX09 EGI60297.1, FBX032 EGI70820.1; for D. melanogaster ntc AAF47792.2, 
CG5961 NP _650206.1 , atrogin NP _648498.1 , for A. gambiae FBX07 XP _565383 .2, 
FBX09 XP _308962.3 and FBX032 XP _320404.2. 
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share an NES inside the leucine charged domain (LCD), an NLS at the amino end of the 
protein, and all but A. gambiae have a second NLS found after the F-box domain. 
Additionally, there is also a highl y conserved potential leucine zipper domain and leucine 
charged domain. The alignment reveals a highly conserved amino terminus that has not 
been previously described (Figure 4). 
The F-box domain in D. melanogaster was compared to the consensus sequence 
(Willems et al., 1999) and by inspection is identified as having fifteen conserved amino 
acid residues (Figure 5). Six of these residues are identical to the consensus sequence and 
nine are conservative substitutions. Notably, the H. sapiens F-box domain has thirteen 
highly conserved identical positions compared to the consensus sequence. 
The F-box proteins atrogin and nutcracker are similar to a certain degree 
The Drosophila F-box protein nutcracker is involved in caspase acti vation during 
sperm differentiation and has been shown to interact with Drosophila PI31. Nutcracker is 
homologous to vertebrate FBX07 (Bader et al., 20 10; Bader et al., 201 1 ). In Drosophila 
melanogaster, the atrogin and nutcracker proteins share some similarity in the PI31 
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Figure 4: The F -box protein atrogin is conserved between vertebrates and 
invertebrates. ClustalW multiple alignment of atrogin proteins. The F-box domain 
(purple), PDZ domain (red), amino terminus (green), LCD (gray), and potential LZ 
(yellow) are highly conserved. The NLS is in teal lettering, the NES in red lettering and 
the foxo binding site is highlighted in light blue. LCD = Leucine charged domain. LZ = 
Leucine zipper domain. NES =Nuclear export sequence. NLS = Nuclear localization 
sequence. "*"indicates fully conserved amino acid posi tion, ":" indicates conservation 
between amino acid groups with highly similar properties, ". " indicates conservation 
between amino acid groups with less similar properties. 
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Figure 5: The F-box domain of atrogin is fairly conserved in both Drosophila 
melanogaster and Homo sapiens at the amino acid level. Consensus sequence of the F-
box motif was obtained from (Willems et al., 1999). The red letters indicate conserved 
residues, upper-case letters indicate identical residues, lower case letters indicate similar 
residues. In the consensus sequence x indicates non-conserved positions. 
atrogin 
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Figure 6: Drosophila F-box proteins atrogin and nutcracker share some similarity. 
ClustaiW multiple alignment of Drosophila atrogin and nutcracker. Highlighted is the 
PI31 binding region of nutcracker (green). "*" indicates full y conserved amino acid 
position,":" indicates conservation between amjno acid groups with highly similar 
properties, "." indicated conservation between amino acid groups with less similar 
properties. 
Effects of the overexpression of atrogin 
Overexpression of atrogin decreases locomotor ability and longevity 
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To determine the effects of the overexpression of atrogin on D. melanogaster 
lifespan and climbing ability, ubiquitous transgenic drivers act-GAlA and arm-GAlA and 
the muscle specific driver mef-GAIA were used. When using mef-GAIA, there was no 
significant difference in locomotor ability between atgnEY; mef-GAIA compared to mef-
GAL4 without a responding transgene or the lacZ-expressing control (Figure 7, Table 3). 
However, the overexpression of atrogin resulted in a significant decrease in climbing 
ability using the high-level ubiquitous driver act-GAlA. There was no significant change 
when the low-level ubiquitous driver arm-GAlA was used (Figure 8, Table 4). 
The overexpression of atrogin using the two ubiquitous drivers resulted in a 
significant decrease in longevity compared to the lacZ-expressing control s (Figure 9). 
The median lifespan for flies overexpressing atrogin using act-GAlA and arm-GAlA 
were 56 and 54 days respectively. This is a much shorter lifespan than that of the controls 
whose median lifespan were 62 and 70 days, respectively (Table 5). 
Overexpression of atrogin decreases ommatidia and bristle number 
The Drosophila melanogaster compound eye develops in a very specific and 
regular pattern. Under normal circumstances, each eye is composed of approximately 800 
ommatidia in a precise structure. The eye is formed as a morphogenetic furrow moves 
from the posterior of the imaginal disc to the anterior. The cell s differentiate and form 
behind this furrow (Baker, 2001 ). Disruption in this process can result in a characteristic 
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Figure 7: Directed muscle specific overexpression of atrogin does not cause a 
significant decrease in climbing ability over time as the flies age. Muscle specific 
overexpression of atroginEY does not show a significant decrease in climbing ability. Data 
was analyzed by a non-linear curve fi t with 95% confidence intervals to determine 
significance. Error bars represent standard error. 
Table 3: Statistical analysis using a non-linear regression curve of locomotor ability 
of flies with the muscle specific overexpression of atroginEY. 
Genotype Slope± SE 95% Significant Significant 
Confidence compared to compared 
Intervals w1118; mef-GAIA to UAS-lacZ/ 
mef-GAIA 
UAS- lacZ; 0.04354 0.01841 - N/A N/A 
me.f-GALA ± 0.01232 0.06866 
atgn I 0.03136 0.02605 - No No 
mef-GALA ± 0.002632 0.03663 
wms 0.03313 0.02626- N/A N/A 
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Figure 8: Directed high-level ubiquitous overexpression of atrogin causes a 
significant decrease in climbing ability over time. Directed low-level ubiquitous 
overexpression does not show a significant decrease in climbing ability. High and low-
level expression was accomplished by using the act-GAlA (A) and arm-GAlA (B) drivers 
respectively. Data was analyzed by a non-linear curve fit with 95% confidence intervals 



































Figure 9: High and low level ubiquitous overexpression of atrogin causes a 
significant decrease in longevity. High-level overexpression was achieved using act-
GAL4 (A) and low-level overexpression was achieved using arm-GAL4 driver (B). 
Longevity is depicted by percent survival. Significance is p < 0 .05 using the log-rank test. 
Error bars represent standard error. 
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Table 4: Statistical analysis using a non-linear regression cur ve of locomotor ability 
of flies with the ubiquitous overexpression of atrogin. 
Genotype Slope ± SE 95% Confidence Significant 
Intervals 
act-GAlA/ 0.03775 ± 0.002681 0.03242 - 0.04307 N/A 
UAS-lacZ 
act-GAlA; 0.03200 ± 0.002468 0.02709 - 0.03690 No 
atgnEY 
arm-GAlA/ 0.04101 ± 0.002691 0.03566 - 0.04636 N/A 
UAS-lacZ 
arm-GAlA; 0.03122 ± 0.002107 0.02705 - 0.03541 Yes ~ 
atgnEY 
Table 5: Log-rank statistical analysis of longevity of flies with ubiquitous 
overexpression of atrogin. Chi-square values and p-values were calculates using lacZ-
expressing controls. 
Genotype Number of Median Survival Chi - square P-value Significant 
flies (da~s) value 
act-GAlA/ 298 62 N/A N/A N/A 
UAS-lacZ 
act-GAlA; 295 56 29.70 <0.0001 Yes ~ 
atgnEY 
arm-GAlA/ 247 70 N/A N/A N/A 
UAS-lacZ 
ann-GAlA; 290 54 93.61 <0.0001 Yes ~ 
atgnEY 
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and/or ommatidia size. These potential phenotypes can be analyzed through biometric 
means to determine the effects of altering gene expression such as the overexpression of 
atrogin. 
To determine the effects of the overexpression of atrogin in the compound eye, 
three GAL4 transgenes were used to express this gene; GMR-GALA to direct expression 
in the eye, a high-level ubiquitous driver act-GALA, and a low-level ubiquitous driver 
arm-GALA. The latter two transgenes direct expression throughout the organism 
including the eye. Analysis of the scanning electron micrographs show that there is a 
small but significant decrease in ommatidia and bristle number when atrogin is 
overexpressed with each driver (Figures 10 and 11). When atrogin is driven by GMR-
GALA, act-GALA and arm-GALA the average number of ommatidia per eye was shown to 
be 650.0 ± 12.63, 636.7 ± 7.672 and 710.1 ± 10.64 respectively. This is compared to the 
lacZ-expressing controls where the average number of ommatidia are 707.5 ± 6.705, 
686.6 ± 9.789, and 757.6 ± 8.431 respectively (Table 6). The overexpression of atrogin 
results in a significant decrease in bristle number. Overexpressing atrogin using the 
drivers GMR-GALA, act-GALA and arm-GALA results in an average bristle number of 
467.7 ± 8.218, 501.6 ± 6.117 and 524.3 ± 10.52 respectively. ControllacZ crosses with 
the same driver lines had a significantly higher number of bristles that averaged to be 
549.5 ± 5.758, 564.0 ± 10.57 and 562.5 ± 15.05 respectively. There was no significant 
difference in ommatidium area detected. 
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Figure 10: Overexpression of atrogin under the control of eye-specific and 
ubiquitous drivers influence ommatidia and bristle number. Scanning electron 
micrographs of A: GMR-GAIA/UAS-lacZ, B: act-GAIA/UAS-lacZ, C: arm-GAL4 /UAS-
lacZ, D: GMR-GAIA;atgnEY, E: act-GAL4;atgnEY, F: arm-GAIA;atgnEY_ GMR-GAIA is 
an eye specific driver and act-GAlA is highly active ubiquitous driver and arm-GAlA is a 
















Figure 11: Biometric analysis of the compound eye under the influence of eye-
specific and ubiquitous atrogin overexpression. Overexpression of atrogin in the eye 
and ubiquitously significantly decreases ommatidia number (A) and bristle number (B). 
There is no significant effect on ommatidium area (C). Significance is p < 0.05. Error 
bars represent standard error of the mean. "*" denotes significant difference, where UAS-
lacZ crosses are the comparison controls. 
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Table 6: Summary of ommatidia number, bristle number and ommatidium area 
when atrogin is overexpressed ubiquitously and in the compound eye. 
Genotype Sample Size Mean± P-value compared to Significant 
(n) SEM control 
Ommatidia Number 
GMR-GALA/ 11 707.5 N/A N/A 
UAS-lacZ ± 6.705 
GMR-GALA; 21 650.0 0.0036 Yes Ill 
atgn EY ± 12.63 
act-GALA/ 10 686.6 N/A N/A 
UAS-lacZ ± 9.789 
act-GAL4; 9 636.7 0.0010 Yes Ill 
atgnEY ± 7.672 
arm-GALA/ 7 757.6 N/A N/A 
UAS-lacZ ± 8.431 
armGALA; 25 710.1 0.0297 Yes Ill 
atgnEY ± L0.64 
Bristle Number 
GMR-GALA/ 11 549.5 N/A NIA 
UAS-lacZ ± 5.758 
GMRGAL4; 21 467.7 < 0.0001 Yes Ill 
atgnEY ± 8.218 
act-GALA 10 564.0 N/A N/A 
IUAS-lacZ ± 10.57 
act-GALA; 9 501.6 0.0001 Yes Ill 
atgnEY ± 6.117 
arm-GALA/ 8 562.5 N/A N/A 
UAS-lacZ ± 15.05 
armGALA; 16 524.3 0.0486 Yes Ill 
atgn EY ± 10.52 
Ommatidium Area 
GMR-GALA/ 11 202.2 N/A N/A 
UAS-lacZ ± 3.025 flm2 
GMRGALA; 2 1 2 11.3 0.2045 No 
atgnEY ± 4.791 flm2 
act-GALA/ 9 202.9 N/A NIA 
UAS-lacZ ± 4.038 flm2 
act-GALA; 9 196.5 0.2063 No 
atgn EY ± 2.832 flm2 
arm-GALA/ 8 214.7 N/A N/A 
UAS-lacZ ± 3.853 flm2 
armGALA; 10 202.0 0.0165 No 
atgnEY ± 5.855flm2 
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Investigation of atrogin and foxo interactions 
Overexpression of atrogin enhances the ''foxo phenotype" in the eye 
To determine if the positive feedback loop between atrogin and foxo seen in 
mammals is conserved in Drosophila the atrogin gene was co-expressed withjoxo 
trans genes. Both a Drosophila version and a mouse version (mfoxo 1) of foxo previously 
generated by our research group (Kramer et al. , 2003) was used to express atrogin and 
f oxo in the eye using drivers GMR-GAL4; UAS-foxo and GMR-GAL4; UAS-m-foxo. The 
elevated expression ofjoxo in the eye generates a characteristic eye phenotype in which a 
substantial number of ommatidia and interommatidial bristles are missing and the surface 
area of the ommatidia is reduced. This is interpreted to indicate that the greater the 
reduction in ommatidia and bristles, the higher the level ofjoxo activity (Kramer et al., 
2003). Analysis of the scanning electron micrographs show that the overexpression of 
atrogin dramatically decreases the number of ommatidia compared to foxo expressing 
controls (Figures 12 and 13). The expression of lacZ as a control transgene, along with 
.foxo, resulted in an average ommatidia count of 398 ± 31.46 and 378 ± 5.130, whereas 
when atrogin was overexpressed withfoxo the averages were 224.3 ± 21. 13 and 153.5 ± 
6.157 for GMR-GAL4; UAS-foxo1 and GMR-GAL4 UAS-m-foxo respectively (Table 7). 
The bristle number was also significantly decreased when atrogin is 
overexpressed withfoxo. When using GMR-GAL4; UAS-foxo 1 the bristle count decreased 
from 2.583 ± 0.9000 on the control to 0.2000 ± 0.1447 when the genes were co-
expressed. When using GMR-GAL4 UAS-m-foxo the count decreased from 30.33 ± 3.957 
on the control to 0.06667 ± 0.06667 in the presence of both atrogin and foxo 
overexpression. Finally, the co-expression of atrogin with foxo results in a significant 
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Figure 12: Overexpression of atrogin withfoxo in the developing compound eye 
enhances thefoxo phenotype. Scanning electron micrographs of A: GMR-GALA/UAS-
lacZ; UAS-foxo1, B: GMR-Ga/4/UAS-lacZ; UAS-m-foxol, C: GMR-GALA; UAS-

















Figure 13: Biometric analysis of atrogin andfoxo overexpression in the compound 
eye. Co-expressing atrogin and foxo together significantly decreases ommatidia number 
(A), bristle number (B) and ommatidium area (C). Significance is p < 0.05. Error bars 
represent standard error of the mean. "*" denotes significance difference, where the UAS-
lacZ crosses are the comparison controls. 
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Table 7: Summary of ommatidia number, bristle number and ommatidium area of 
atrogin andfoxo co-expression in the compound eye. 
Genotype Sample Mean±SEM P-value compared Significant 
Size (n) to control 
Ommatidia Number 
GMR-GAL4/ 10 398 N/A N/A 
UAS-lacZ; UAS-foxo I ± 31.46 
GMR-GAL4; 28 224.3 0.0001 Yes II' 
UASJoxo 1/ atgnEY ± 21.13 
GMR-Gal4 30 378 N/A N/A 
UAS-m-foxol ± 5.130 
UAS-lacZ 
GMR-GAL4 31 153.5 < 0.0001 Yes II' 
UAS-m-foxo; atgn EY ± 6.157 
Bristle Number 
GMR-GAL4/ 12 2.583 N/A N/A 
UAS-lacZ; UAS-foxo I ± 0.9000 
GMR-GAL4; 15 0.2000 0.0074 Yes II' 
UAS/oxo 1/ atgnEY ± 0.1447 
GMR-Gal4 15 30.33 N/A N/A 
UAS-m-foxol ± 3.957 
UAS-lacZ 
GMR-GAL4 15 0.06667 <0.0001 Yes II' 
UAS-m-foxo; atgnEY ± 0 .06667 
Ommatidium Area 
GMR-GAL4/ 10 196.6 N/A N/A 
UAS-lacZ; UAS-joxo1 ± 2.748 ~m2 
GMR-GAL4; 18 166.8 < 0.0001 Yes II' 
UAS-foxo 11 atgnEY ± 2.982 !Jffi2 
GMR-Gal4 20 185.2 N/A N/A 
UAS-m-foxol ± 3.141 !Jffi2 
UAS-lacZ 
GMR-GAL4 26 171.2 0.0065 Yes II' 
UAS-mJoxo; atgnEY ± 3.546 !Jffi2 
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decrease in ommatidium area compared to the control. The area of ommatidium in GMR-
GALA/UAS-lacZ; UAS-foxo1 averaged to 196.6 ± 2.748 J.!m2 compared to GMR-GAL4; 
UAS-foxo 1! atgnEY where the average was 166.8 ± 2.982 J.!m2. For GMR-Gal4 UAS-m-
foxo!UAS-lacZflies the ommatidium area was 185.2 ± 3.141 J.!m2, versus 171.2 ± 3.546 
J.!m2 in GMR-GALA UAS-m-foxo!atgnEY flies. 
Overexpression of atrogin increases survivorship during amino acid starvation 
The atrogin gene was ubiquitously expressed using act-GALA and arm-GALA in 
flies aged on amino acid-deprived media. The presence of foxo activity decreases the 
flies sensi tivity to starvation and enables a longer period of survival under these 
conditions (Kramer et al., 2008). Therefore if the positive feedback loop between foxo 
and atrogin is conserved, overexpression of atrogin may result in an increase in 
survivorship. When atrogin was overexpressed using both act-GALA and arm-GALA the 
ability to withstand starvation was significantly increased (Figure 14) to median survival 
days of 28 and 36 respectively. This is compared to the lacZ-expressing controls where 
the median survival was 26 days (Table 8). To complement thi s study, loss of function 
(lof) atrogin mutants atgnEY (in the absence of GAL4) and atgnKG were aged on amino 
acid depleted media and resulted in a decrease of longevity to median survival days of 18 
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Figure 14: Ubiquitous overexpression of atrogin increases survivorship in times of 
amino acid deprivation. High-level overexpression was achieved using act-GAlA (A) 
and low-level overexpression was achieved using arm-GAlA (B). Longevity is depicted 
by percent survival. Significance is p < 0.05 using the log-rank test, where UAS-lacZ 
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Figure 15: Mutants atgnEY and atgnKG significantly decreases longevity during amino 
acid starvation compared to overexpression of atrogin and the control. Longevity is 
depicted by percent survival. Significance is p < 0.05 using the log-rank test, where UAS-
lacZ crosses is the comparison control. Error bars represent standard error. 
Table 8: Log-rank statistical analysis of longevity of flies under amino acid 
starvation with ubiquitous overexpression of atrogin and mutant atrogin. Chi-square 
values and p-values were calculates using UAS-lacZ controls. 
Genotype Number of Median Chi - square P-value Significant 
flies Survival (da~s) value 
act-GAlA/ 306 26 N/A N/A N/A 
UAS-lacZ 
act-GAlA; 224 28 25 .88 <0.000 1 Yes ~ 
atgnEY 
arm-GAlA/ 349 26 N/A N/A N/A 
UAS-lacZ 
arm-GAL4; 339 36 292.4 <0.0001 Yes ~ 
ats.nEY 
EY 308 18 105.5 <0.0001 Yes ~ atgn 
atgnkc 287 20 68. 16 <0.0001 Yes ~ 
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Investigation of GMR-GAIA; UAS-foxoH1 and the effect akt has on atrogin and {oxo 
To determine if akt affects the possible interaction between atrogin and foxo, all 
three genes were overexpressed in the compound eye. For these studies, a novel insertion 
of Drosophila UAS-foxo, UAS-foxoH1 was examined. This was generated by 
transposition of the original UASjoxo 1 transgene (Kramer et al., 2003) from the third to 
the second chromosome with preliminary observations suggesting that expression of this 
transgene in the eye leads to more moderate phenotypes compared to the original. The 
atrogin and akt genes were overexpressed using the novel GMR-GAIA; UAS-foxoH1 
driver. A recombinant line GMR-GAL4; UAS-foxoHI; atgnEY was created to allow the 
overexpression of three genes in a single fly. 
The new transgenic insertion GMR-GAIA; UAS-foxoH1 showed no significant 
change in ommatidia number from the UAS-lacZ control (Figures 16 and 17). However, 
there was a significant increase in ommatidia number from GMR-GAL4; UAS-foxo 1 
(398.7 ± 31.46) to GMR-GAIA; UAS-foxoH1 (693.8 ± 12.22). GMR-GAIA; UAS-foxoH1 
had a bristle count of 124.7 ± 17.12 which is a significant decrease compared to GMR-
GAIA/UAS-lacZ at 549.4 ± 5.758, but a significant increase compared to GMR-GAL4; 
UAS-foxo 1 at 2.583 ± 0.9000. Ommatidium area of GMR-GAL4; UAS-foxoH1 (198.5 ± 
2.623 JJ.m2) was not significantly different from GMR-GAL4; UAS-foxo, but was 
decreased compared to GMR-GAL4/UAS-lacZ (202.2 ± 3.025 JJ.m2) (Table 9). 
To determine the effects akt has on the atrogin/foxo interaction, two akt 
transgenes were used; a bovine version of akt, UAS-b-akt and the Drosophila homologue, 
UAS-akt. There was no significant difference in bristle number between crosses GMR-
GAL4/UAS-lacZ; UASjoxoHI; atgnEY and GMR-GAL4 UAS-foxoH1/ UAS-b-akt;atgnEY 
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Figure 16: The expression of akt protein does not influence the interaction of 
atrogin on foxo when co-expressed in the compound eye. Scanning electron 
· HI HI 
micrographs of A: GMR-GAIA UAS-foxo / UAS-lacZ B: GMR-GAIA UAS-foxo IUAS-
b-akt C: GMR-GAIA UAS-foxoH1/UAS-akt 0: GMR-GAIA UAS-foxoH1/UAS-lacZ; atgnEY 
E: GMR-GAIA UAS-foxoH1/UAS-b-akt; atgnEY F: GMR-GAIA UAS-foxoH1/UAS-akt; 






Figure 17: Newly generated transgenic insertion UAS-foxoH1 shows a weaker 
phenotype than UAS-foxo when driven by GMR-GA IA. There is no significant change 
in ommatidia number (A) in GMR-GAIA UAS-foxoH1/UAS-lacZ compared to the control 
GMR-GAIA/ UAS-lacZ. Bristle number (B) was reduced in both GMR-GAIA UAS-
foxoH1/UAS-lacZ and GMR-GAIA/UAS-lacZ;UAS-foxo1, however a much more severe 
reduction was seen in the latter. There was a significant difference in ommatidium area 
(C) in GMR-GAIA UAS-foxoH 1/UAS-lacZ compared to GMR-GAIA/ UAS-lacZ. " * " 
denotes significance, where significance difference is p < 0.05. 
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Table 9: Summary of ommatidia number, bristle number and ommatidium area of 
novel transgene insertion UAS-foxoH1 under the control of GMR-GAIA. 
Genotype Sample Mean P-value Significant P-value Significant 
Size (n) ±SEM compared to GMR- compared to GMR-
to GMR- GAIA/ to GMR- GAIA; 
GAIA/ UAS-lacZ GAIA; UAS-foxo1 
UAS-lacZ UAS-foxo 1 
Ommatidia Number 
GMR- 1 1 707.5 N/A N/A N/A N/A 
GAIA/ ± 6.705 
VAS-lacZ 
GMR- 10 398.7 N/A N/A N/A N/A 
GAL4/ ± 31.46 
VAS-lacZ; 
VAS-foxo 1, 
GMR-GAIA 15 693 .8 0.3820 No <0.0001 Yes ~ 
VASfoxoH11 ± 12.22 
VAS-lacZ 
Bristle Number 
GMR- 11 549.5 N/A N/A N/A N/A 
GAIA/ ± 5.758 
VAS-lacZ 
GMR- 12 2.583 N/A N/A N/A N/A 
GAIA/ ± 0.900 
VAS-lacZ; 
VAS}oxo 1, 
GMR-GAIA 15 124.7 <0.0001 Yes ~ <0.0001 Yes ~ 




GMR- 11 202.2 N/A N/A N/A N/A 
GAIA/ ± 3.025 
VAS-lacZ m 2 
GMR- 10 196.6 N/A N/A N/A N/A 




GMR-GAIA 15 189.5 0.0041 Yes ~ 0.0834 No 
VAS- ± 2.623 
f oxoH11 llffi2 
VAS-lacZ 
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(Figure 18). However, there was a significant increase in bristle number in GMR-GAL4 
UAS-foxoH1/UAS-b-akt at 481.4 ± 5.532 compared to GMR-GAL4 UAS-foxoH1 IVAS-lacZ 
at 124.7 ± 17.12 (Table I 0). There was a significant decrease in bristle number in GMR-
GAL4/UAS-akt; UAS-foxo1/atgn£Y (109.9 ± 48.30) compared to GMR-GAL4/UAS-akt; 
UAS-foxo 1 (367.6 ± 41.92). 
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Genotype 
Figure 18: Biometric analysis of the compound eye under the co-expression of akt, 
atrogin andfoxo. The overexpression of bovine-akt rescues the decrease in bristle 
number due to foxo overexpression. The overexpression of atrogin does not affect this 
rescue. The overexpression of Drosophila-akt partially rescues the decrease in bristle 
number, which is slightly inhibited by the overexpression of atrogin. Significance is p < 
0.05. Error bars represent standard error of the mean. 
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Table 10: Summary of bristle number under the coexpression of atrogin, akt and 
foxo. 
Genotype Sample Mean P-value Significant P-value Significant 
Size ± compared to VAS- compared toGMR-
(n) SEM to VAS- lacZ to GMR- GAIA; 
lacZ control GAIA; VAS-
control VAS-foxoH1 foxoHI 
control control 
Bristle Number 
GMR-GAIA 15 124.7 N/A NIA N/A N/A 
UAS-foxoH1/ ± 
UAS-lacZ 17. 12 




GMR-GAIA 15 481.4 <0.0001 Yes ~ NIA N/A 
UAS-foxoH1/ ± 
UAS-b-akt 5.532 




GMR-GAIA 18 367.6 <0.0001 Yes N/A NIA 
UAS-foxoH1/ ± 
UAS-akt 41.92 





Investigation of the potential interaction between atrogin and PI31 
Since atrogin (FBX032) and nutcracker (FBX07) are closely related, it was 
examined if there was any redundancy in function between the two proteins. To 
determine any potential effects atrogin may have on P/31 both genes were co-expressed 
in the compound eye using the driver GMR-GAL4 transgene. There is a significant 
decrease in ommatidia number, bristle number and ommatidium area in GMR-
GA L4/UAS-P/31; atgnEY compared to the control GMR-GAL4/ UAS-lacZ; atgnEY (Figures 
19 and 20). Ommatidia number decreases from 743.2 ± 8.230 to 705.1 ± 6.769 and bristle 
number decreases from 584.3 ± 4.474 to 519.4 ± 4.794. Ommatidium area decreases from 
550.2 ± 6.99 1 f.!m2 to 527.6 ± 8.163 f.!m2 (Table 11). The GMR-GAL4/ UAS-P/31 critical 
class individuals reveal significant disruption of the ommatidia, therefore ommatidia 
number or ommatidium area could not be analyzed. The very significant level of 
disruption was completely rescued by co-overexpression of atrogin. Although not 
unexpected, the bri stle number is significantly decreased in GMR-GAL4/UAS-PI31 
individuals to a level of 41 4.5 ± 8.694 compared to 57 1.8 ± 6.543 in GMR-GAL4/ UAS-
lacZ. The GMR-GAL4/ UAS-P13 1; atgnEY show a partial suppression of thi s phenotype by 
increasing the number of bristles compared to GMR-GAL4/UAS-P/31 individuals. 
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Figure 19: The overexpression of atrogin rescues the ommatidia fusion phenotype 
caused by the overexpression of P/31. Scanning electron micrographs of A: GMR-
GAIA/UAS-lacZ B: GMR-GAIA/UAS-lacZ; atgnEY C: GMR-GAIA/UAS-P/31 D: GMR-















Figure 20: Biometric analysis of the compound eye under the directed co-expression 
of atrogin and PI31 in the eye. Overexpression of atrogin and PI31 together 
significantly decrease ommatidia number (A), bristle number (B), and ommatidium area 
(C). Ommatidia number and ommatidium area could not be analyzed for GMR-
GAIAIUAS -?131. The overexpression of atrogin suppresses the ommatidia fus ion 
phenotype and decrease in bristle number caused by PI31 overexpression, P131 slightly 
influences growth of the eye in the presence of atrogin overexpression in the eye. Bristle 
number was reduced in GMR-GAIA/UAS-P/31 compared to GMR-GAIAIUAS-lacZ. 
Significance is p < 0.05. Error bars represent standard error of the mean. "*" denotes a 
significant difference. 
58 
Table 11: Summary of ommatidia number, bristle number and ommatidium area 
under the directed expression of atrogin and P/31 in the compound eye. 
Genotype Sample Mean P-value Significant P-value Significant 
Size (n) ±SEM compared to VAS- compared to GMR-
to VAS- lacZ toGMR- GAIA 
lacZ control GAIA control 
control control 
Ommatidia Number 
GMR-GAL41 12 751.0 N/A N/A N/A N/A 
UAS-lacZ ± 9.357 
GMR-GAL4/ 13 743.2 0.5336 No N/A N/A 
UAS-lacZ; ± 8.230 
atgnEY 
GMR-GAL4/ N/A N/A N/A N/A N/A N/A 
UAS-P/31 
GMR-GAL4/ 16 705.1 0.0012 Yes ~ N/A N/A 
UAS-P/31; ± 6.769 
atgnEY 
Bristle Number 
GMR-GAL4/ 12 571.8 N/A N/A N/A N/A 
UAS-lacZ ± 6.543 
GMR-GAL4/ I I 584.3 0.1381 No N/A N/A 
UAS-lacZ; ± 4.474 
atgn EY 
GMR-GAL4/ 6 414.5 <0.0001 Yes N/A N/A 
UAS-P/31 ± 8.694 
GMR-GAL4/ 15 519.4 <0.00 1 Yes ~ <0.001 Yes 
UAS-P/31; ± 4.794 
atgn EY 
Ommatidium Area 
GMR-GAL4/ 12 182.6 N/A N/A N/A N/A 
UAS-lacZ ± 3.611 
m2 
GMR-GAL4/ 13 183.4 0.8636 No N/A N/A 
UAS-lacZ; ± 2.330 
at n EY m2 
GMR-GAL4/ N/A N/A N/A N/A N/A N/A 
UAS-P/31 
GMR-GAL4/ 15 175.9 0.0496 Yes ~ N/A N/A 
UAS-P/31; ± 2.721 
atgn EY m2 
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Characterization of atgnEY derivative mutants 
To generate a deletion mutation of atrogin, the EPgy2 P-element of 
P( EPgy2}CGJ 1658EYI OJ IS was excised and selected for the loss of the transposon's "mini-
white" marker gene by Dr. Brian E. Staveley to create 26 novel mutants. Through PCR 
and sequence analysis, it was determined 1) which of the EPgy2 sequences remained 
and/or 2) which of the atrogin gene or neighbouring mtTBI gene sequences were excised 
along with the P-element. Of the 26 derivative lines, there were twenty mutants retaining 
portions of the EPgy2 insertion with between approximately 50 to 800 base pairs 
remaining. Three other mutants retained only one end of the P-element. The mutant 
designated atgn16a was the only one to have the complete P-element remaining while 
atgn8 had a reversion to wild type, or alternatively a complete deletion of EPgy2 without 
any genomic deletion. Only two of the new mutants were determined to possess 
significant deletions where portions of neighbouring genes were missing. Mutant atgn40 
has approximately 1300 bases of the atrogin gene missing and mutant atgn13a has 21 
bases of EPgy2 remaining, a 30 base atrogin deletion and a 1204 base mtTFBI deletion 
(Table 12). Mutant atgn4a has a significant deletion of the atrogin gene between bases II 
701 883 - II 700 560 on chromosome 3. This includes the coding DNA sequence (CDS) 
of atrogin. Mutant atgn 130 is missing the region between II 703 235 - 1 1 701 607 which 
includes the CDS of the mtTFBJ (Figure 21). The latter may likely be a null allele of 
mtTFBI and the atgn40 allele should represent a null allele of the atrogin gene. 
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Table 12: Analysis of atgnEY derivative mutants to determine deletion of the atrogin 
gene and/or EPgy2 P-element. 
Genotype Homozygously Primers used to -PCR - Insertion or 
Viable obtain fragment fragment deletion (bp) 
size (b~) 
Controls 
w Yes atgn F4 atgn R3 500 N/A 
atgn F4 atgn R5 NIA 
atgn F4 atgn R6 1700 
atgn F8 atgn R3 1700 
atg_n R3 atgn F7 N/A 
atgnEY Yes atgn F4 atgn R3 N/A NIA 
atgn F4 atgn R5 650 
atgn F4 atgn R6 N/A 
atgn F8 atgn R3 N/A 
atgn F7 atgn R3 500 
atgn mutants 
atgn7a Yes atgn F4 atgn R3 1000 500 EPgy2 
insertion 
atgn Yes atgn F7 atgn R3 500 Intact 3-prime end 
of EPg~2 
atgn 2a Yes atgn F4 atgn R3 1300 800 EPgy2 
insertion 
atgn 7 Yes atgn F4 atgn R3 550 50 EPg~2 insertion 
atgn3 Yes atgn F4 atgn R3 1300 800 EPgy2 
insertion 
atg_n a Yes atgn F4 atg_n R6 400 1300 atg_n deleted 
4b Yes atgn F4 atgn R3 650 150 EPgy2 atgn 
insertion 
atgn Yes atgn F4 atgn R3 >650 150 EPgy2 
insertion 
atgn No atgn F4 atgn R3 900 400 EPgy2 
insertion 
atgn Yes atgn F4 atgn R3 650 150 EPgy2 
insertion 
atgn No atgn F4 atgn R3 500 EPg~2 deleted 
atgn9 Yes atgn F4 atgn R3 1300 800 EPgy2 
insertion 
atgn Yes atgn F4 atgn R3 1300 800 EPgy2 
insertion 
atgn Yes atgn R3 atgn F7 500 Intact 3-prime end 
of EPg~2 
atgn 72a Yes atgn F4 atgn R3 1300 800 EPgy2 
insertion 
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atgn a No atgn F8 atgn R3 300 21 EPgy2 insertion 
30 atgn and 1204 
mtTFBI deleted 
atgn a No atgn F4 atgn R3 1300 800 EPgy2 
insertion 
atgn No atgn F4 atgn R3 1250 750 EPgy2 
insertion 
atgn a Yes atgn F4 atgn R5 650 5-prime end of 
EPg~2 intact 
atgn76a Yes atgn F7 atgn R3 450 3 and 5-prime ends 
atgn F4 atgn R5 650 of EPg~2 intact 
atgn 77 Yes atgn F8 atgn R3 1700 800 EPgy2 
insertion 
atgn No atgn F4 atgn R3 650 150 EPgy2 
insertion 
atgn No atgn F4 atgn R3 575 75 EPg~2 insertion 
atgn20 Yes atgn F4 atgn R3 650 150 EPgy2 
insertion 
atgn Yes atgn F4 atgn R3 650 150 EPgy2 
insertion 
atg_n Yes atg_n F4 atgn R3 520 20 EPg~2 insertion 
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11 693 188 11 701663 11 702 031 11703 670 
~ I I ) A atgn mtTFB1 I I 
11700 511 11 702 599 
Start of CDS Sta rt of CDS 
11 693 188 11 701 663 11 702 031 11 703 670 
l:~ _____ at_g_n __ ~~------E_P_gy~2------~~~~--~~~ ~-m_t_T_F_B_1 __ ~:) 
I I 
11 700 511 11 701633 11702 599 
B 
Start of CDS Start of CDS 
11 693 188 
~ ~0560 
11 702 0 3 1 
~ mtTFBl 
11 701883 
11 703 670 
) c 
11 693 188 11 701 607 
~ I atgn \ ~-----.--'---
1 
11 700 511 
11 703 670 ? D 
11 703 235 
Start of CDS 
Figure 21: Schematic representation of the wild type atrogin and mtTFBl genes, the 
atgnEY insertion, and deJection mutants with large deletions. A: wild type atrogin B: 
EY C 4a D /3a N b . d. b . . atgn : atgn mutant : atgn mutant. urn ers m tcate ase positiOn on 
chromosome 3. CDS= coding DNA sequence. Mutant atgn40 has a deletion in the 
atrogin gene. Mutant atgnlJa has a deletion in the mtTFBJ gene. 
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Generation of UAS-atrogin transgenic flies 
As the experiments described herein relied upon the atrogin insertion line, 
transgenic UAS-atrogin flies were created for the easier manipulation of overexpression 
of atrogin during future experiments. From the progeny of one of the surviving injected 
individuals (original generation - GO), two female critical class progeny (generation one -
G l) were identified by selecting for the red-pigmented eye phenotype. These females 
were each mated with w 1118 males. However, these females progeny produced offspring 
(generation two- G2) in which red-eyed males were absent, and approxmately 50% of 
the females had red-eyes. The lack of red-eyes indicate that the transgene is not present. 




The atrogin F-box protein has been identified as FBX032 in several species 
including H. sapiens, M. musculus, R. norvegicus, S. salar and 0. mykiss. The protein 
functions in the ubiquitin proteasome pathway, where it is a component of an E3 ligase, 
the SCF complex, and aids in skeletal muscle atrophy. As an FBXO protein, atrogin 
provides the specificity and rate of ubiquitination as it is the protein that binds the target 
substrate (Bodine et al., 2001 a; Gomes et al., 2001; Lecker et al., 2004; Tacchi et al., 
2010; Cleveland and Evenhuis, 2010). FBX032 has been implicated in a number of 
diseases and chronic conditions where muscle wasting occurs. These include cancer, 
rheumatoid arthritis, sepsis, AIDS, renal failure, COPD, immobilization, and spinal cord 
injury (Foletta eta/. , 2011). By expanding the knowledge of the function and targets of 
atrogin new opportunities may open for therapies of the various diseases. 
Unti l now, little research has been conducted on the atrogin homologue in 
Drosophila melanogaster. The Drosophila homologue has been identified as Drosophila 
gene CCI 1658, and since then it has been found that the Drosophila muscle wasting 
mutant has increased expression of gene CCI 1658 (Bulchand et al., 2010). However, 
this current study is the first to explore various aspects of the Drosophila melanogaster 
homologue of atrogin. Specifically, atrogin was ectopically expressed to examine the 
effects it has on longevity, locomotion, survivorship in times of nutritional stress, cell 
death and cell growth. 
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Drosophila atrogin is homologous to mammalian atrogin 
Bioinformatic analysis was first conducted on the Drosophila atrogin homologue 
to determine the similarity between CGJ 1658 and FBX032 in several other species, as 
well as its relationship to other closely related FBXO proteins. As expected, when a 
cladogram was constructed with four FBXO proteins, CG 11658 clustered together with 
FBX032 indicating that it is more closely related to this protein than any of the other 
FBXO's. Since the F-box genes cluster together, and not the species, it may be inferred 
that the FBXO genes existed in the common ancestor of the species and evolved with that 
species. FBX032 and FBX025 are more closely related to each other than to FBX07 or 
FBX09, however FBX025 is only found in vertebrate species. FBX025 is analogous to 
atrogin being 65% simj1ar and sharing structural features such as the PDZb domain and 
NLS. However, their distributions differ, as FBX025 is not found in skeletal muscle but 
is in high abundance in the brain, kjdney and intestine (Maragno et al., 2006). A separate 
study in humans and mice found that FBX025 is an E3 ligase that targets cardiac 
transcription factors Nkx2-5, Isll, Hand I and Mef2C for proteasomal degradation (Jang 
et al., 20 11 ). Characterization of FBX025 in 0. my kiss and S. salar is in agreement 
where the results show that the mRNA is not increased during food deprivation, 
indicating that it is not involved in skeletal muscle atrophy (Cleveland and Evenhuis, 
20 l 0; Tacchi et al., 20 I 0). The atrogin gene may have duplicated throughout time and 
evolved into FBX025 in vertebrates. It is possible that FBX032 in invertebrates such as 
D. melanogaster and A. echinator has undiscovered roles in different organs such as the 
brain, since FBX025 is not present. 
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The F-box motif is not well conserved throughout evolution as seen by the 
relatively few invariant amino acid positions. The motif binds Skp I to form the SCF 
complex and functions in the UPS (Bai et al., 1996). While the Drosophila F-box motif 
was not identifiable though in silica searches, manual analysis shows that it is 35% 
conserved compared to the consensus sequence provided by Willems et al. The human 
FBX032 F-box motif is 30% conserved, but has more highly conserved residues 
compared to Drosophila. The Drosophila F-box motif may be more conserved since the 
consensus sequence was constructed from the yeast, S. cerevisiae. The amino terminus is 
highly conserved between the four species examined. Due to its high level of 
conservation, it can be inferred that there were tight evolutionary constraints placed on 
this region. Thus, this previously unidentified region may serve an important unknown 
biological function. Both serine and threonine amino acids are fully conserved and they 
may serve as phosphorylation sites. The proline amino acid residue appears to be 
conserved throughout evolution, and may serve to aid in the folding of the secondary 
structure. Further studies are needed to allude to the function of this novel amino 
terminus. Again, the Drosophila PDZ domain was not identifiable through in silica 
searches, but manual analysis show that it is conserved between vertebrates and 
invertebrates. It is a class two PDZ domain since it follows the pattern X<DX<I>cooH where 
X is any amino acid and <I> is a hydrophobic amino acid (Songyang et al. , 1997; Tonikian 
et al. , 2008). The domain functions to serve as a protein-protein recognition domain, and 
may serve to bind substrates that are targeted for ubiquitination by atrogin. The foxo 
binding region in atrogin is well conserved between mice and humans, however further 
studies must be conducted to determine the foxo binding sites on Drosophila. Taken 
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together, this bioinformatic analysis shows that Drosophila CGJ 1658 is homologous to 
mammalian atrogin. However, at the amino acid level it is not extremely well conserved, 
but this is to be expected as many F-box proteins evolved over time especially FBXO's. 
Effect of atrogin overexpression in Drosophila 
The development of the Drosophila compound eye is tightly regulated and 
controlled to form a precise structure. The formation begins with eight photoreceptor 
cells where both mitotic and survival signalling dictates the final ommatidia number. This 
enables apoptosis and cell size to be studied, by examining ommatidia number and size, 
as well as bristle number. The eye is also composed of sensory bristles, which allows for 
the examination of neurogenesis (Baker, 2001 ). This strict formation of the compound 
eye allows even the slightest defects to be amplified, detected and examined. 
The present experiments demonstrate that in Drosophila, overexpression of 
atrogin directly in the eye through eye-specific or ubiquitous expression results in a 
decrease in ommatidia and bristle number, but no overall change in ommatidium size. 
The low-level ubiquitous dri ver arm-GAlA resulted in sl ightly smaller reductions when 
compared to the other transgenes and this may be due to decreased expression levels. The 
decrease in ommatidia number is slight, but is detectable through biometric analysis. This 
may be due to a small increase in apoptosis or a decrease in the growth and survival 
signalling required for successful eye development. Both scenarios may be explained by 
a potential increase in foxo activation due to an increase in atrogin expression that leads 
to its nuclear localization (Li et al., 2007a). Once inside the nucleus, Drosophila foxo can 
initiate the transcription of its pro-apoptotic target genes (Zhang et al., 20 II). Therefore, 
68 
a potential increase in apoptosis may account for the decrease in ommatidia and bristle 
number seen when atrogin is overexpressed. Alternatively, another reason for only a 
slight decrease in ommatidia number may be due to the fact that the compound eye is 
largely composed of neuronal tissue. The atrogin SCF complex may not ubiquitinate 
proteins in the eye for degradation to produce an obvious phenotype. 
To determine the effects that atrogin overexpression has on Drosophila lifespan 
standard longevity assays were conducted. Ubiquitous overexpression of atrogin 
significantly decreases longevity under standard conditions. No previous studies that 
examined longevity in association with atrogin expression have been reported, therefore 
the reason for this reduction in lifespan is unclear. However, is has been recentl y shown 
that mammalian atrogin associates with enzymes that are a part of glycolysis and 
gluconeogeneisis and may be targeting these for degradation (Lokireddy et al. , 20 12).1f 
thi s function is evolutionary conserved, this may be one reason for decreased lifespan in 
Drosophila in the presence of increased atrogin expression. Additionally, when using the 
high-level ubiquitous driver act-GAL4, there was a less of a decrease in longevity than 
when using arm-GAL4. Again, this may be due to an increase in functional foxo. In act-
GAL4, there was a larger increase in atrogin expression, and therefore a probable greater 
increase in foxo activation. Overexpression studies in C. elegans show that daf-16 is a 
necessary factor to mediate an increase in lifespan due to a decrease in insulin signalling 
(Henderson and Johnson, 2001). Studies of Drosophila mutants have shown similar 
results where foxo acts to increase longevity during aging (Yamamoto and Tatar, 2011). 
This can be described as an evolutionary trade off between growth and survival, where a 
decrease in growth correlates with an increase in lifespan. However, this possible 
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increase in foxo was not enough to overcome the decrease in lifespan due to an increase 
in atrogin and resulted in an overall reduction of longevity. 
As the atrogin gene has been shown to be expressed at increased levels during 
skeletal muscle atrophy, a climbing assay may detect the subtle consequences of such 
muscle atrophy in Drosophila. Consistent with this theory, the overexpression of atrogin 
resulted in a significant decrease of locomotor ability when using the high-level 
ubiquitous driver act-GAL4. This may be due to a predicted decrease in muscle synthesis 
and/or an increase in muscle atrophy. The SCF-complex within which atrogin functions 
has been shown to target MyoD (Tintignac et al., 2005) and eiF3-f for degradation 
(Lagirand-Cantaloube et al., 2008). Both of these proteins are essential for muscle 
synthesis, therefore new muscle cannot be produced. More recently, studies have also 
shown that atrogin targets light and heavy muscle filaments for degradation in mice 
during myostatin induced muscle atrophy (Lokireddy et al., 2011 b). Hence, there are at 
least two established mechanisms through which atrogin may promote muscle atrophy, 1) 
a decrease in muscle synthesis and 2) an increase in muscle proteolysis. There are four 
myogenic regulatory factors (including MyoD) in vertebrates, and in Drosophila the one 
homologue is known as nautilus. The nautilus regulatory factor is involved in embryonic 
mesoderm formation, and in the differentiation of specific muscle fibers (Balagopalan et 
al., 200 I ; Michelson et al., 1990). There is an eiF3-f homologue in Drosophila currently 
identified as CG9769. If Drosophila atrogin is able to target nautilus or CG9769 for 
degradation, this may explain the decrease in locomotor ability during increased atrogin 
expression. Alternatively, another explanation of the reduced locomotor abil ity may 
simply be accelerated senescence and premature ageing. However, there are inconsistent 
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results when using different GAL4 transgenes. With the low-level ubiquitous arm-GAlA 
driver, there was no significant difference in climbing ability detected over time, which 
may be a result of a variation in expression levels. When using the muscle specific driver 
mef-GAIA there was also no significant difference when atrogin was overexpressed. 
Drosophila mef2 is a myocyte enhancer factor that is a critical component in myogenic 
differentiation, and therefore muscle growth (Lilly et al., 1994). It is possible that 
Drosophila atrogin may also target mef2 for degradation, therefore atrogin will not be as 
highly expressed due to the fact that the activating factor, a critical component to the 
UAS-GAL4 system, is being degraded. 
Drosophila atrogin and foxo interaction 
In addition to targeting skeletal muscle proteins for degradation, atrogin is a 
downstream component of the insulin receptor signalling pathway, which aids in the 
positive regulation of the foxo family of transcription factors (Li et al., 2007a). When 
activated, foxo can initiate the transcription of genes that can promote apoptosis, regulate 
body size and metabolism, cause an arrest in cell cycle, and increase longevity (Barthel et 
al., 2005). Two Drosophila foxo phenotypes were used in this study to shed light on the 
potential interaction between foxo and atrogin: 1) development of fewer ommatidia and 
interommatidial bristles in the compound eye and 2) increased survival during nutritional 
stress. 
With the overexpression ofjoxo under the control of the GMR-GAIA transgene, 
the eye is missing many ommatidia and bristles (Kramer et al., 2003). It can be inferred 
that the higher the level of active foxo, the more ommatidia and bristles will be absent. In 
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the present study atrogin appears to increase the activation of foxo as seen by a decrease 
in ommatidia number, bristle number and ommatidia area when atrogin andfoxo were 
co-expressed in the developing eye. This is consistent with previous findings found in 
mice. The murine foxo family of transcription factors binds to an SCF complex through 
atrogin to become ubiquitinated. However, this polyubiquitin chain is not recognized by 
the 26S proteasome, because it a lysine-63 linked rather than lysine-48 linked chain (Li et 
a!., 2007a). Drosophila atrogin may ubiquitinate foxo with a lysine-63 linked 
polyubiquitin chain since there is an increase in foxo activation. If foxo was tagged with a 
lysine-48 linked polyubiquitin chain, there would be a decrease in foxo causing an 
increase in ommatidia and bristle count. The polyubiquitin chain on foxo may be 
preventing deactivation by akt, therefore foxo is able to localize in the nucleus and 
initiate the transcription of its target genes. In mammals, it has been shown that the 
atrogin gene is a transcriptionally controlled by foxo, therefore an increase in foxo results 
in an increase in atrogin (Sandri et al., 2004; Skurk et al. , 2005). If this relationship is 
conserved in Drosophila, it is possible that this could induce a large reduction in 
ommatidia number in the developing eye. 
A decrease in ommatidia area is seen when atrogin andfoxo are co-expressed 
together in the developing eye, but this decrease was not observed when atrogin was 
expressed alone. In vitro atrophy studies have shown that an increase in atrogin 
transcription correlates with a decrease in myotube (Sandri et al., 2004) and myocyte 
diameter (Skurk et al., 2005). The overexpression of atrogin in the differentiating 
compound eye does not decrease the area of the ommatidia, possibly due to the non-
muscular character of the eye or, perhaps because the expression level was not high 
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enough. When atrogin and foxo are expressed together, the functional activity of the foxo 
transcription factor appears to be elevated. A simple explanation is that the foxo 
transcriptional activity may be increased due to the ubiquitination activity resulting in 
movement to the nucleus. Alternatively, it is possible the positive feedback loop between 
the two is activated, resulting in a higher level of atrogin expression, in the presence of 
elevated foxo leading to elevated foxo expression. When atrogin was overexpressed 
withoutfoxo, the threshold needed to cause a decrease in cellular growth as seen by a 
reduction of ommatidia area may not have been reached. 
In all organisms there is a balance between cellular growth and longevity, and 
foxo appears to be a central component in regulating this balance. Drosophila foxo is 
required for optimal survival during times of nutritional stress such as ami no acid 
deprivation. A loss of foxo study has shown decreased survivorship during starvation 
compared to flies with fully functional foxo (Kramer et al. , 2008). An overexpression 
study in Drosophila larvae showed that an increase in foxo mimics the growth arrest 
phenotype shown during starvation (Kramer et al. , 2003). The foxo transcription factors 
regulate the balance between growth and survival and provide the protective mechanisms 
during times of decreased nutrition (Demontis and Perrimon, 2010). Therefore, an 
increase in foxo activation can cause an increase in survivorship during times of nutrient 
deprivation. This current study shows that the overexpression of atrogin using both high 
and low-level ubiquitous dri vers resul ts in an increase in survivorship when under 
nutritional stress, while loss of function mutants have decreased ability to tolerate 
starvation. A probable cause of thi s is the increase of activated foxo during increased 
atrogin expression. As previously mentioned, Drosophila atrogin may be activating foxo, 
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which then enters the nucleus to initiate the transcription of its target genes. In this case, 
the target genes act to cause an arrest in the cell cycle promoting longevity. 
A novel foxo insertion line UAS-foxoH1 has been introduced in this current study. 
This was done in order to readily create a recombinant line with GMR-GAL4 UAS-foxoH1 
and atgnEY so that both transgenes are on the same chromosome. It can be clearly seen 
that the novelfoxo insertion provides a much weaker phenotype compared to the original 
UAS-foxo 1 in response to GMR-GAIA. Compared to previous studies, the UASJoxoH1 
transgenes respond differently compared to the UAS-foxo 1 to produce insignificant 
decreases in ommatidia number and size when compared to wild type. However, GMR-
GAIA UAS-foxoH' does show a great decrease in bristle number compared to wild type, 
although this is not as large of a decrease as seen in GMR-GAIA UAS-foxo 1• Thus, bristle 
number can be analyzed in GMR-GAIA UAS-foxoH1 individuals. 
The current study shows that both UAS-akt and UAS-b-akt rescues the decrease in 
bristle number caused by GMR-GAIA UAS-foxoHJ. When using the bovine akt transgene, 
the decrease in bristle number was rescued to wi ld type levels. However, when using 
Drosophila akt, there is only a partial rescue of the phenotype as the bristle count does 
not reach control levels. This is in agreement with a previous study where overexpression 
of UAS-akt along with GMR-GAIA UAS-foxo 1 rescues thefoxo eye phenotype (Kramer et 
al., 2003). This is due to the effect that the akt kinase has upon the foxo transcription 
factor. The akt kinase is known to phosphorylate foxo, aiding to exclude it from the 
nucleus (Brunet et al., 1999). If foxo is unable to enter the nucleus, it cannot initiate the 
transcription of its target genes, which provide the foxo phenotype. The bovine version of 
akt seems to be a more active or efficient insertion as the foxo phenotype is fully rescued, 
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indicating little to no active foxo. However, the Drosophila akt transgene is not able to 
return the bristle number to control levels. This may be explained by the variation in 
expression levels between UAS-akt and UAS-b-akt with the Drosophila akt leading to a 
much weaker expression. 
When the effect of atrogin is studied alongside akt, there are differing results 
between the overexpression of Drosophila and mammalian akt. The potential effects of 
the ubiquitination of foxo due to atrogin did not modify the activation status of foxo 
when bovine akt is overexpressed as there is no significant difference in bristle number 
HI EY · HI between GMR-GAIA UAS-foxo I UAS-b-akt; atgn and GMR-GAIA UAS-foxo I VAS-
b-akt. Here, akt may be phosphorylating foxo and excluding it from the nucleus, 
therefore the foxo phenotype is not present. However, when UAS-akt is overexpressed 
alongside with GMR-GAL4 UAS-foxoH1 and atroginEY, there is a decrease in bristle 
number compared to just UAS-akt and GMR-GAIA UAS-foxoH1 alone. In this case, atrogin 
may be able to ubiquitinate foxo thereby allowing the nuclear retention of foxo and 
possibly preventing the phosphorylation of foxo by akt. The difference seen between the 
two akt constructs may again be explained by relative expression levels. If UAS-b-akt has 
a greater expression level, there may be enough akt present in the cell to phosphorylate 
nearly all the foxo and override the effect atrogin has on foxo. If UAS-akt has a reduced 
expression level, therefore there may not be enough akt available to counteract the 
ubiquitination of foxo by atrogin. Alternatively, UAS-b-akt and UAS-akt may have 
similar expression levels, but UAS-b-akt may be more efficient in phosphorylating foxo, 
thereby excluding is from the nucleus. 
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Previous studies in mammals have produced conflicting results when trying to 
establish if the insulin receptor signalling pathway, through akt activity, can counteract 
the effect of atrogin upon foxo. One study has shown that the upregulation of atrogin that 
occurs due to an increase in angiotensin II, can be blocked by the activation and 
phosphorylation of akt as a result of the activation of the insulin signalling pathway 
(Yoshida et al. , 2010). Another study in cardiac muscle has shown that constitutively 
active akt inhibits the expression of atrogin and therefore inhibits atrophy (Skurk et al., 
2005). While another study has reveled that IGF-1 can block skeletal muscle atrophy 
induced by glucocorticoids by inhibiting the activation of foxo (Stitt et al., 2004). 
However, it has been shown that overexpression of atrogin can inhibit cardiac 
hypertrophy regardless of the phosphorylation state of akt or its downstream targets. 
Furthermore, the same study has shown that atrogin alone can inhibit the phosphorylation 
of foxo caused by the activation of the insulin receptor signalling pathway and that a 
decrease in atrogin corresponds with an increase in phosphorylated foxo (Li et al., 
2007a). Therefore, further studies are needed to determine the affect akt has on the 
interaction between atrogin and foxo. 
Possible interaction between Drosophila atrogin and PI31 
In Drosophila, atrogin and nutcracker (FBX07) are partially similar at the amino 
acid level. Therefore, the possible redundancy in function between atrogin and nutcracker 
was examined. In Drosophila , nutcracker regulates caspase activation, which ultimately 
controls sperm differentiation (Bader et al. , 20 I 0), since most of the sperm contents are 
eliminated before final individualization (Arama et al. , 2003). For nutcracker to become 
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fully functional , it must bind with its binding partner PI31. PI31 promotes normal 
proteasomal function that is required during sperm differentiation and is stabilized by 
nutcracker (Bader et al., 20 II ). Both nutcracker and Drosophila P/3 I appear to be 
functionally homologous to their FBX07 and P/3I mammalian counterparts. 
When P/3I was overexpressed in the developing eye, a significant disruption in 
the ommatidia) array was generated. This disruption was so severe that the ommatidia 
number and size could not be analyzed. However, when both Pl3I and atrogin were 
overexpressed, this phenotype was almost completely rescued. The overexpression of 
atrogin mostly rescues the reduction in bristle number caused by the overexpression of 
P/3 I. Since there have been no previous studies examining the interaction between 
atrogin and PI31 in any species, or the overexpression of P/31 in the eye, the reasons for 
these results are unclear. One possible explanation is that without a binding partner, PI31 
is deleterious and causes the ommatidia disruption and bristle reduction. With the 
addition of atrogin, PI3 1 may have a partner in atrogin, and therefore not cause the 
disrupted phenotype. 
By overexpressing both Drosophila atrogin and P/3 I , there was a significant 
decrease in ommatidia number and size compared to the expression of the atrogin gene 
alone. As stated, atrogin may be suppressing the destructive effects that PI3 1 alone has on 
the compound eye. However, this suppression may not be enough to overcome all of the 
damaging effects. PI31 may be increasing proteolysis (Bader et al., 201 1) to cause the 
decrease in ommatidia number and size. 
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Creation of novel atrogin mutants and transgenic flies 
Of the novel mutants characterized, two particularly promising and unique novel 
mutants have been created through the imprecise excision of the EPgy2 P-element in 
atroginEY. Mutant atgn4a is missing the entire P-element along with a large portion of the 
atrogin gene, while atgn13a is missing the P-element and a portion of the neighbouring 
gene, mtTFBJ . Two central components of both genes are eliminated, the transcriptional 
start site and the protein-coding DNA sequence, rendering the genes non-functional. 
Without the transcriptional start site, mRNA cannot by formed from the gene and without 
a protein-coding DNA sequence, protein cannot be created. The mutant atgn4a is a viable 
homozygote indicating that a functional atrogin gene is not required for development 
from larvae to adult. 
However, atgn13a is not viable as a homozygous adul t, and only survives as larvae 
and pupa. Therefore, a functioning mtTFBJ seems to be essential for development from 
pupa to adul t flies. Knock down studies of mtTFBJ in Drosophila have shown that it is 
required for modulating mitochondrial translation (Matsushima et al., 2005). Obviously, 
normal regulation of mitochondrial translation is essential for Drosophila development. 
Transgenic UAS-atrogin flies were successfully created as indicated by the 
presence of w +eyes in the progeny of the injected w 11 18 Drosophila embyros. Since it was 
inserted onto the X-chromosome as a lethal insertion, the next step will be to have it 
transposed as a viable insertion onto another chromosome. Without this extra step, males 
with a functional insertion will not survive, limiting the usefulness of this line in 
Drosophila assays. Once the insertion is moved onto a non-lethal site in the genome, 
further analysis of the effects of overexpressing may be performed. 
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Conclusion 
Through the present study, the Drosophila melanogaster homologue of atrogin 
has been identified and characterized. While it is not very highly conserved at the amino 
acid level, it appears to be functionally conserved as overexpression of atrogin decreases 
longevity and locomotor ability. The potential interaction between foxo and atrogin can 
increase longevity during nutrient deprivation and can increase apoptosis, indicating 
increased levels of foxo activation. Further studies are needed to examine the interaction 
between atrogin and foxo at the molecular and cellular level including microarray and q-
PCR analysis. Additionally, further research must be undertaken to determine the effect 
akt has on the atrogin and foxo interaction. Novel atgn4a mutant can be examined for 
further studies into loss of function of atrogin, where as the novel transgenic UAS-atrogin 
can be used for further overexpression studies. The influence of atrogin on muscle 
degeneration is another area of research that will be undertaken. This current research has 
laid the foundation for further in depth studies of atrogin. 
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Schematic diagram of the ubiquitin proteasome pathway. Adapted from 
(Murton et al. , 2008) 
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Schematic diagram of the climbing apparatus used to assay locomotor ability in 
Drosophila. Adapted from Todd and Staveley 2004. 
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